taurine has been researched along with Alcohol Abuse in 366 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Acamprosate, although not approved in the United States, is used in alcoholism treatment in many other parts of the world." | 10.19 | Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. ( Kranzler, HR; Van Kirk, J, 2001) |
| "Data were collected during an 8-week randomized controlled trial of acamprosate for individuals with co-occurring bipolar disorder and alcohol dependence (n = 30)." | 9.16 | Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. ( Brady, KT; Brown, DG; Chiuzan, C; DeSantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
| "Naltrexone and acamprosate have been shown to be effective in relapse prevention of alcoholism via different pharmacologic mechanisms." | 9.10 | Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. ( Baehr, M; Briken, P; Helwig, H; Holzbach, R; Jahn, H; Kämpf, P; Kiefer, F; Naber, D; Stracke, R; Tarnaske, T; Wiedemann, K, 2003) |
| " We review recent meta-analyses showing the superior effectiveness of supervised disulfiram (SD) in alcoholism treatment compared with oral naltrexone or acamprosate (ACP)." | 8.95 | Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects. ( Brewer, C; Skinner, M; Streel, E, 2017) |
| "The present study compared two putative pharmacotherapies for alcohol abuse and dependence, dehydroepiandrosterone (DHEA) and pregnanolone, with two Food and Drug Administration (FDA)-approved pharmacotherapies, naltrexone and acamprosate." | 7.81 | Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats. ( Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ, 2015) |
| "Taurine (TAU) and compounds representing a TAU analog (hypotaurine = HYTAU) or homolog (aminomethanesulfonic acid = AMSA, homotaurine = HMTAU) were tested for their counteracting effects against alterations in erythrocyte (RBC) morphology, membrane fluidity and cytoskeletal spectrin distribution due to diabetes, alcoholism and diabetes-alcoholism in male Goto-Kakizaki rats (made diabetic with a high fat diet and alcoholic upon feeding on a flavored alcohol solution) and Wistar-Kyoto rats (serving as controls)." | 7.75 | The effects of taurine, hypotaurine, and taurine homologs on erythrocyte morphology, membrane fluidity and cytoskeletal spectrin alterations due to diabetes, alcoholism and diabetes-alcoholism in the rat. ( Gossai, D; Lau-Cam, CA, 2009) |
| "Acamprosate was well-tolerated, with no worsening of depressive or manic symptoms, and appeared to confer some clinical benefit in study completers in the last two weeks of the trial." | 6.77 | A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. ( Brady, KT; Brown, DG; Desantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
| "Acamprosate was discontinued in nine patients (1%) because of severe adverse events; only two cases were clearly linked to treatment (diarrhoea and dermatitis)." | 6.70 | Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. ( Preuss, U; Schuetz, C; Soyka, M, 2002) |
| "Acamprosate was well tolerated." | 6.69 | Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. ( Aeby, F; Besson, J; Kasas, A; Lehert, P; Potgieter, A, 1998) |
| " Acamprosate, although not approved in the United States, is used in alcoholism treatment in many other parts of the world." | 6.19 | Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. ( Kranzler, HR; Van Kirk, J, 2001) |
| " Psychotherapy is the mainstay of treatment for alcoholism, while few drugs approved by legislators are available in the augmentation of this treatment, such as acamprosate, disulfiram, and naltrexone, approved by the FDA, and nalmefene by the EMA." | 5.41 | Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective. ( Gorczyca, P; Piegza, M; Pudlo, R; Stokłosa, I; Stokłosa, M; Więckiewicz, G, 2023) |
| "Acamprosate has a different mechanism of action than other drugs used for maintenance of abstinence from alcohol and is generally well tolerated." | 5.33 | Acamprosate campral for alcoholism. ( , 2005) |
| " Chronic administration of acamprosate reduced both alcohol and water drinking during SIP, but did not significantly affect regulatory drinking or non-drinking measures." | 5.33 | Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. ( Escher, T; Mittleman, G, 2006) |
| "The goal of the current study was to use tree-based methods to identify moderators of acamprosate effect on abstinence from heavy drinking in COMBINE, the largest study of pharmacotherapy for alcoholism in the United States to date." | 5.20 | An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. ( Fucito, L; Gueorguieva, R; O'Connor, PG; O'Malley, SS; Tsai, WM; Wu, R; Zhang, H, 2015) |
| "Data were collected during an 8-week randomized controlled trial of acamprosate for individuals with co-occurring bipolar disorder and alcohol dependence (n = 30)." | 5.16 | Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. ( Brady, KT; Brown, DG; Chiuzan, C; DeSantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
| "These results suggest a potential mechanism by which acamprosate mediates its therapeutic effect in the treatment of alcoholism, by attenuating the urge to drink following an alcohol slip." | 5.14 | The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. ( Beck, O; Franck, J; Hammarberg, A; Jayaram-Lindström, N; Reid, MS, 2009) |
| "Acamprosate and naltrexone are effective medications in the treatment of alcoholism." | 5.14 | Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. ( Daoust, M; Houchi, H; Koeter, MW; Naassila, M; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R, 2009) |
| "Acamprosate is approved for the treatment of alcoholism, but its mechanism of action remains unclear." | 5.14 | Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. ( Adams, LJ; Doty, L; George, DT; Heilig, M; Hommer, D; Lifshitz, M; Momenan, R; Schwandt, ML; Shen, J; Singley, E; Spanagel, R; Umhau, JC; Vengeliene, V; Zhang, Y, 2010) |
| "The National Institute on Alcohol Abuse and Alcoholism COMBINE (Combining Medications and Behavioral Interventions) study, a randomized controlled double-blind trial of 1,383 alcohol-dependent patients, compared combinations of medications (acamprosate [Campral] and naltrexone [ReVia]) and behavioral therapy (medical management and specialist-delivered behavioral therapy) for alcohol dependence." | 5.13 | Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. ( Hosking, JD; Locastro, JS; O'malley, SS; Swift, R; Weiss, RD, 2008) |
| "To evaluate whether individuals with alcoholism who are heterozygous (Asp40/Asn40) or homozygous (Asp40/Asp40) for the OPRM1 Asp40 allele respond better to naltrexone." | 5.13 | An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. ( Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R, 2008) |
| "In 160 patients suffering from alcoholism, we measured plasma adrenocorticotropic hormone (ACTH) and cortisol during placebo-controlled relapse prevention treatment with naltrexone and/or acamprosate." | 5.12 | Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? ( Jahn, H; Kiefer, F; Naber, D; Otte, C; Wiedemann, K, 2006) |
| "Acamprosate and naltrexone have been shown to be effective in relapse prevention of alcoholism." | 5.12 | The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. ( Koeter, MW; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R, 2007) |
| "The efficacy of pharmacological relapse prevention in alcoholism with acamprosate and naltrexone has been supported by several controlled trials." | 5.11 | Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. ( Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K, 2005) |
| "Naltrexone and acamprosate have been shown to be effective in relapse prevention of alcoholism via different pharmacologic mechanisms." | 5.10 | Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. ( Baehr, M; Briken, P; Helwig, H; Holzbach, R; Jahn, H; Kämpf, P; Kiefer, F; Naber, D; Stracke, R; Tarnaske, T; Wiedemann, K, 2003) |
| " In 1997, the National Institute on Alcohol Abuse and Alcoholism recruited 11 sites and a coordinating center for a large-scale (1,375 subjects), randomized placebo controlled trial to test 16 weeks of active treatment using naltrexone and acamprosate alone and in combination." | 5.10 | Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. ( , 2003) |
| " We review recent meta-analyses showing the superior effectiveness of supervised disulfiram (SD) in alcoholism treatment compared with oral naltrexone or acamprosate (ACP)." | 4.95 | Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects. ( Brewer, C; Skinner, M; Streel, E, 2017) |
| "This article explores the mechanisms of action and the potential responder profile of acamprosate, a compound efficacious in relapse prevention of alcoholism." | 4.84 | Acamprosate: recent findings and future research directions. ( Kiefer, F; Littleton, J; Mann, K; Spanagel, R, 2008) |
| "Naltrexone and acamprosate may ultimately prove to be useful additions to pharmacotherapy for alcoholism by reducing relapse." | 4.82 | Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. ( Littleton, J; Zieglgänsberger, W, 2003) |
| "Relevant information was identified through searches of MEDLINE (1966 to March 2005), International Pharmaceutical Abstracts (1970-2005), Current Contents (1996-2005), and Cumulative Index to Nursing and Allied Health Literature (1982-Week 2, 2004) using the key words acamprosate, alcohol dependence, and alcoholism (MeSH)." | 4.82 | Acamprosate for the treatment of alcohol dependence. ( Boothby, LA; Doering, PL, 2005) |
| " The presentations were (1) Pharmacological validation of a new animal model of alcoholism, by Rainer Spanagel; (2) Persisting loss of control as main criterion for alcohol addiction in rats and mice, by Jochen Wolffgramm; (3) Role of NMDA receptor subunits associated with protein kinase C in the prevention of alcohol dependence, by Minoru Narita; (4) Long-term follow up of continued naltrexone treatment, by David Sinclair; (5) Pharmacological treatment trials with dopaminergic and serotonergic substances: Myths or facts? by Gerhard A." | 4.81 | Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials. ( Boening, JA; Lesch, OM; Mason, BJ; Narita, M; Sinclair, D; Spanagel, R; Wiesbeck, GA; Wolffgramm, J, 2001) |
| "Recent reports documenting that naltrexone and acamprosate are more effective than placebo in the treatment of alcoholism justify clinical interest in use of these medications for alcohol-dependent patients." | 4.80 | Pharmacological treatment of alcohol dependence: a review of the evidence. ( Carey, TS; Crews, FT; Garbutt, JC; Lohr, KN; West, SL, 1999) |
| " In addition the possible mode of action of a new therapeutic drug for the treatment of alcoholism, acamprosate will be discussed." | 4.80 | Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. ( Dahchour, A; De Witte, P, 2000) |
| "The present study compared two putative pharmacotherapies for alcohol abuse and dependence, dehydroepiandrosterone (DHEA) and pregnanolone, with two Food and Drug Administration (FDA)-approved pharmacotherapies, naltrexone and acamprosate." | 3.81 | Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats. ( Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ, 2015) |
| " Food and Drug Administration (FDA) for use in the treatment of alcohol abuse and alcoholism--disulfiram, naltrexone, and acamprosate." | 3.76 | Pharmacotherapies for alcoholism: the old and the new. ( Olive, MF, 2010) |
| " Patients treated with oral naltrexone hydrochloride(n = 2064), oral disulfiram (n = 2076), oral acamprosate calcium (n = 5068), or extended-release injectable naltrexone (naltrexone XR) (n = 295) were also compared for 6-month utilization rates of alcoholism medication, inpatient detoxification days, alcoholism-related inpatient days, and outpatient services, as well as inpatient charges." | 3.76 | Comparison of healthcare utilization among patients treated with alcoholism medications. ( Chalk, M; Gastfriend, DR; Kranzler, HR; Mark, TL; Montejano, LB, 2010) |
| "Taurine (TAU) and compounds representing a TAU analog (hypotaurine = HYTAU) or homolog (aminomethanesulfonic acid = AMSA, homotaurine = HMTAU) were tested for their counteracting effects against alterations in erythrocyte (RBC) morphology, membrane fluidity and cytoskeletal spectrin distribution due to diabetes, alcoholism and diabetes-alcoholism in male Goto-Kakizaki rats (made diabetic with a high fat diet and alcoholic upon feeding on a flavored alcohol solution) and Wistar-Kyoto rats (serving as controls)." | 3.75 | The effects of taurine, hypotaurine, and taurine homologs on erythrocyte morphology, membrane fluidity and cytoskeletal spectrin alterations due to diabetes, alcoholism and diabetes-alcoholism in the rat. ( Gossai, D; Lau-Cam, CA, 2009) |
| "The aim of this study was to evaluate the beta-endorphin (beta-endorphin) plasma level in Warsaw Low Preferring (WLP) and Warsaw high-preferring (WHP) rats after repeated administration of acamprosate, one of most effective drug in the treatment of alcoholism." | 3.73 | Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. ( Cwiek, W; Czarnecka, E; Dyr, W; Zalewska-Kaszubska, J, 2005) |
| "Acamprosate (Campral) is a drug used clinically for the treatment of alcoholism." | 3.73 | The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. ( Adams, C; Cowen, MS; Kraehenbuehl, T; Lawrence, AJ; Vengeliene, V, 2005) |
| " For the National Institute on Alcohol Abuse and Alcoholism COMBINE Study, testing the safety and efficacy of naltrexone and acamprosate, both alone and in combination, in the treatment of alcohol dependence, we adapted a standardized instrument--the Systematic Assessment for Treatment Emergent Events (SAFTEE)--for assessing adverse events in these Phase 2- to Phase 3-type studies." | 3.73 | The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. ( Ait-Daoud, N; Johnson, BA; Roache, JD, 2005) |
| "Treatment with acamprosate, a compound used for relapse prevention treatment of alcoholism, was recently shown to be associated with increased plasma concentration of beta-endorphin in rats selectively bred for high alcohol preference." | 3.73 | Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. ( Jahn, H; Kiefer, F; Nakovics, H; Otte, C; Wiedemann, K, 2006) |
| "The average percentages of physicians' patients with alcoholism who were prescribed the following medications were: 13% (naltrexone), 9% (disulfiram), 46% (antidepressants) and 11% (benzodiazepines)." | 3.72 | Physicians' opinions about medications to treat alcoholism. ( Bransberger, P; Crosse, S; Kranzler, HR; Mark, TL; Poole, VH; Song, X, 2003) |
| "Acamprosate has been shown to be effective and safe in relapse prevention of alcoholism." | 3.72 | [Acamprosate--new preclinical research aspects]. ( Mann, K; Spanagel, R, 2003) |
| " The effect of neramexane, a low-to-moderate affinity uncompetitive NMDA receptor antagonist, was examined on the development and expression of ethanol dependence (withdrawal-associated audiogenic seizures) and ethanol-induced conditioned place preference." | 3.72 | Effect of neramexane on ethanol dependence and reinforcement. ( Biala, G; Bochenski, M; Danysz, W; Kotlinska, J; Rafalski, P, 2004) |
| " Exposure-induced but not spontaneous alcohol intake is antagonized by acamprosate, a compound clinically effective in human alcoholism." | 3.71 | Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. ( Arlinde, C; Heilig, M; Rimondini, R; Sommer, W, 2002) |
| "Acamprosate, which has been shown to down-regulate the glutamatergic system, may be particularly effective for relief drinkers." | 2.84 | Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. ( Mann, K; Roos, CR; Witkiewitz, K, 2017) |
| "Acamprosate has been found to enhance rates of complete abstinence and to increase percent days abstinent (PDA) from alcohol relative to placebo treatment." | 2.78 | Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study. ( Beier, N; Berger, L; Bohn, M; Brondino, M; Fisher, M; Ford, A; Garbutt, JC; Greco, J; Gwyther, R; Longo, L, 2013) |
| "Acamprosate was well-tolerated, with no worsening of depressive or manic symptoms, and appeared to confer some clinical benefit in study completers in the last two weeks of the trial." | 2.77 | A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. ( Brady, KT; Brown, DG; Desantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
| "Cigarette smoking predicts more severe alcohol dependence and poorer treatment response in general." | 2.77 | Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. ( Fucito, LM; Gueorguieva, RV; Gulliver, SB; Mattson, ME; O'Malley, SS; Park, A, 2012) |
| "Empirically-supported treatments for alcohol dependence exist, yet understanding of influences contributing to the intended behavior change is limited." | 2.76 | Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence. ( Donovan, D; Hartzler, B; Villarroel, N; Witkiewitz, K, 2011) |
| "Acamprosate was well tolerated during the entire course of the study." | 2.72 | Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. ( Boeijinga, P; Danel, T; Gendre, I; Landron, F; Luthringer, R; Muzet, M; Staner, L, 2006) |
| "13 acamprosate-treated and 13 placebo-treated patients completed the treatment phase: of those withdrawn, 11 (1 vs 6) relapsed, 5 (3 vs 2) refused to continue treatment, 3 (1 vs 2) had concurrent illness, and 2 (1 vs 1) had adverse side-effects." | 2.71 | Acamprosate and its efficacy in treating alcohol dependent adolescents. ( Niederhofer, H; Staffen, W, 2003) |
| "At 11 sites, 108 individuals with alcohol dependence were randomized in a double blind fashion to receive placebo, naltrexone, or acamprosate alone or in combination." | 2.71 | Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. ( , 2003) |
| "Acamprosate seems to be an effective treatment for alcohol dependence in a Brazilian population." | 2.71 | Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. ( Baltieri, DA; De Andrade, AG, 2004) |
| "Acamprosate treatment had no effect on basal or CRH-stimulated ACTH or cortisol secretion." | 2.71 | Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate. ( Holsboer, F; Koller, G; Soyka, M; Spring, K; Zimmerman, U, 2004) |
| " Thus, this is the first human pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone." | 2.70 | A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. ( Boyeson, MG; Dixon, RM; Goodman, AM; Hameed, MH; Hulot, T; Hunter, JA; Mason, BJ; Wesnes, K, 2002) |
| "Acamprosate was discontinued in nine patients (1%) because of severe adverse events; only two cases were clearly linked to treatment (diarrhoea and dermatitis)." | 2.70 | Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. ( Preuss, U; Schuetz, C; Soyka, M, 2002) |
| "105 patients with severe alcohol dependence, who were treated in 13 centers in Switzerland, took part in this open study." | 2.70 | [Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland]. ( Fuchs, WJ; Riebenfeld, D, 2002) |
| "Acamprosate was well tolerated." | 2.69 | Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. ( Aeby, F; Besson, J; Kasas, A; Lehert, P; Potgieter, A, 1998) |
| "Acamprosate 1995 mg/day was given for 6 months for relapse prevention with all patients being abstinent throughout the study." | 2.69 | Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics. ( Aichmüller, C; Möller, HJ; Preuss, U; Soyka, M, 1998) |
| "94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase: of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness, three (two vs one) died, ten (six vs four) had adverse side-effects, one (acamprosate treated) received the wrong medication, and three (placebo treated) were non-compliant." | 2.68 | Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. ( Fischer, F; Fleischhacker, WW; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Whitworth, AB, 1996) |
| "Acamprosate proved to be a safe and effective aid in treating alcohol-dependent patients and in maintaining the abstinence of patients during 2 years." | 2.68 | Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. ( Mann, K; Sass, H; Soyka, M; Zieglgänsberger, W, 1996) |
| "Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions." | 2.68 | Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. ( Gavrilovic, M; Le Bon, O; Lehert, P; Lion, K; Pelc, I; Verbanck, P, 1997) |
| "The development of alcohol dependence is associated with significant morbidity and mortality." | 2.55 | Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. ( Goh, ET; Morgan, MY, 2017) |
| "Alcohol addiction is a heterogeneous psychiatric disorder according to both phenotype and etiology." | 2.53 | NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION. ( Cicin-Šain, L; Kovak-Mufić, A; Marušić, S; Matošić, A; Vidrih, B, 2016) |
| "Acamprosate was associated with a reduction in risk of discontinuing treatment for Europe (RR = 0." | 2.52 | The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. ( Donoghue, K; Drummond, C; Elzerbi, C; Pilling, S; Saunders, R; Whittington, C, 2015) |
| "Alcohol use disorders are common, but only a small minority of patients receive adequate treatment." | 2.52 | Recent Developments in Pharmacotherapy of Alcoholism. ( Lieb, M; Soyka, M, 2015) |
| "Insomnia in patients with alcohol dependence has increasingly become a target of treatment due to its prevalence, persistence, and associations with relapse and suicidal thoughts, as well as randomized controlled studies demonstrating efficacy with behavior therapies and non-addictive medications." | 2.52 | Assessment and treatment of insomnia in adult patients with alcohol use disorders. ( Brower, KJ, 2015) |
| " Acamprosate is generally well tolerated, has a low propensity for drug interactions and may be used without dosage adjustment in patients with mild to moderate hepatic impairment, although dosage adjustments or contraindications are recommended in patients with renal impairment." | 2.52 | Acamprosate: A Review of Its Use in Alcohol Dependence. ( Plosker, GL, 2015) |
| "Several treatments for alcohol dependence have been tested in randomized controlled trials, giving rise to systematic reviews with a network of evidence structure, or mixed treatment comparisons (MTCs)." | 2.50 | A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials. ( DeSantis, SM; Zhu, H, 2014) |
| "Naltrexone is effective to treat alcohol dependence (decreased length and frequency of drinking bouts), but its severe side effects, including withdrawal symptoms, are difficult to overcome." | 2.50 | Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. ( Liang, J; Olsen, RW, 2014) |
| "Globally, alcohol abuse and dependence are significant contributors to chronic disease and injury and are responsible for nearly 4% of all deaths annually." | 2.50 | The development of acamprosate as a treatment against alcohol relapse. ( Kufahl, PR; Olive, MF; Watterson, LR, 2014) |
| "The efficacy of medications for alcohol dependence remains modest, and there are no strong clinical predictors of treatment response." | 2.49 | Pharmacotherapy for alcohol dependence: status of current treatments. ( Franck, J; Jayaram-Lindström, N, 2013) |
| "Acamprosate was also associated with significantly higher rates of treatment completion (p = 0." | 2.48 | Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. ( Lehert, P; Mason, BJ, 2012) |
| "In Poland the main treatment method of alcohol addiction is psychotherapy practiced in the rehab centers." | 2.48 | [The patient with an alcohol abuse problem family doctor practice]. ( Kuźniar-Placek, J; Panasiuk, L; Szponar, J, 2012) |
| "Treatment with acamprosate was found to accrue a net benefit of 21,301 BEF (528 €) per patient over a 24-month period in Belgium and lifetime benefit for each patient in Spain was estimated to be Pta." | 2.47 | A literature review of cost-benefit analyses for the treatment of alcohol dependence. ( Duhig, A; Mohapatra, S; Patra, J; Popova, S; Rehm, J, 2011) |
| "Alcoholism is one of the most prevalent substance dependence disorders in the world." | 2.46 | Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. ( Heyser, CJ; Mason, BJ, 2010) |
| "Developing pharmacotherapies to treat alcohol dependence and associated health problems traditionally has been based on gaining a better understanding of the neuroscience underlying alcohol-drinking behavior." | 2.44 | Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. ( Krishnan-Sarin, S; Krystal, JH; O'Malley, S, 2008) |
| "Alcohol dependence is a widespread psychiatric disorder." | 2.44 | Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review. ( Rösner, S; Soyka, M, 2008) |
| "Disulfiram is an inhibitor of the enzyme aldehyde dehydrogenase and acts as an alcohol-deterrent drug." | 2.44 | Preclinical and clinical pharmacology of alcohol dependence. ( Quertemont, E; Tambour, S, 2007) |
| "Acamprosate has demonstrated efficacy for treating alcohol dependence in European trials, but with a small effect size." | 2.44 | Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. ( Johnson, BA, 2008) |
| "Acamprosate has been commercially available in the USA since 2004 to treat alcohol dependence." | 2.44 | Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. ( Crean, R; Mason, BJ, 2007) |
| "Acamprosate was shown only to support abstinence; it did not influence alcohol consumption after the first drink." | 2.44 | Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. ( Lehert, P; Leucht, S; Rösner, S; Soyka, M, 2008) |
| "Prevalence of alcohol dependence remains stable across time between 5-7% in men and 2-3% in women, corresponding to at least 1." | 2.44 | [Alcohol dependence: diagnosis and treatment]. ( Blanc, F; Perney, P; Rigole, H, 2008) |
| "Acamprosate is a proven effective intervention in the treatment of alcohol dependence." | 2.43 | Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. ( Geerlings, PJ; Koeter, MW; Lehert, P; van den Brink, W; Verheul, R, 2005) |
| "Acamprosate is an abstinence-promoting drug widely used in the treatment of alcohol dependence but which has a mechanism of action that has remained obscure for many years." | 2.43 | Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. ( De Witte, P; Koob, G; Littleton, J; Parot, P, 2005) |
| "Acamprosate is a synthetic taurine analogue that seems to act centrally to restore the normal activity of glutamatergic neurotransmission altered by chronic alcohol exposure." | 2.43 | Acamprosate in the treatment of alcohol dependence. ( Mason, BJ, 2005) |
| " Data from dose-response studies for acamprosate alone suggest that the augmentation of acamprosate plasma levels by co-administration of naltrexone may have clinical benefits." | 2.43 | Rationale for combining acamprosate and naltrexone for treating alcohol dependence. ( Mason, BJ, 2005) |
| "Medications for treating alcohol dependence primarily have been adjunctive interventions, and only three medications--disulfiram, naltrexone, and acamprosate--are approved for this indication by the U." | 2.43 | Medications for treating alcohol dependence. ( Williams, SH, 2005) |
| "Relapse prevention for alcohol dependence has traditionally involved psychosocial and psychotherapeutic interventions." | 2.43 | Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. ( Jung, YC; Namkoong, K, 2006) |
| "Acamprosate has a significant beneficial effect in enhancing abstinence in recently detoxified, alcohol-dependent individuals." | 2.42 | The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. ( Lehert, P; Mann, K; Morgan, MY, 2004) |
| "Acamprosate was associated with a significant improvement in abstinence rate [odds ratio (OR): 1." | 2.42 | Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. ( Amate, JM; Angeles, M; Bouza, C; Magro, A; Muñoz, A, 2004) |
| " The relative paucity of dose-response studies on naltrexone's effects in treating alcoholics is an important gap in the literature." | 2.41 | Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. ( Ait-Daoud, N; Johnson, BA, 2000) |
| "Therefore, pharmacologic treatments for alcohol dependence may be targeted to numerous pathways." | 2.41 | Pharmacologic approaches to the management of alcoholism. ( Anton, RF, 2001) |
| "Acamprosate was generally well tolerated in placebo-controlled trials." | 2.40 | Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. ( Wagstaff, AJ; Wilde, MI, 1997) |
| " In particular, issues addressed include alternative dosage regimens, necessary duration of treatment, employment of medications in combination, integration of pharmacologic agents with behavioral interventions, enhancement of patient compliance, and concurrent treatment of psychiatric comorbidity." | 2.40 | Advances in development of medications for alcoholism treatment. ( Allen, JP; Litten, RZ, 1998) |
| "Acamprosate is a relatively new drug that appears to be clinically useful in the treatment of alcohol dependence." | 2.39 | Acamprosate in alcohol dependence: how does it work? ( Littleton, J, 1995) |
| "Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal symptoms followed by psychotherapy in inpatient and/or outpatient settings." | 2.39 | The pharmacological treatment of alcohol dependence: needs and possibilities. ( Mann, K, 1996) |
| "Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal symptoms followed by psychotherapy in inpatient and/or outpatient settings." | 2.39 | The pharmacological treatment of alcohol dependence: needs and possibilities. ( Mann, K, 1996) |
| "Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD)." | 1.72 | Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. ( Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Ho, MF; Karpyak, VM; Li, H; Moon, I; Oesterle, TS; Seppala, MD; Skime, MK; Wei, L; Weinshilboum, RM; Zhang, C; Zhang, L, 2022) |
| "Pharmacotherapy for Alcohol Dependence (AD) is underutilized." | 1.62 | Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012. ( Agabio, R; Balia, S; Gessa, GL; Pani, PP, 2021) |
| "To evaluate drug therapy for alcohol dependence in the 12 months after first diagnosis in UK primary care." | 1.46 | Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. ( Ashcroft, DM; Owens, L; Pirmohamed, M; Thompson, A; van Staa, TP, 2017) |
| "Among US military veterans, alcohol use disorder (AUD) is prevalent and in severe cases patients need intensive AUD treatment beyond outpatient care." | 1.46 | Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. ( Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, AD; Timko, C; Wong, JJ, 2017) |
| "To examine use of first-line alcohol use disorder (AUD) medications (naltrexone and acamprosate) among public drug plan beneficiaries in the year following an AUD diagnosis." | 1.46 | First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. ( Gomes, T; Martins, D; Singh, S; Spithoff, S; Turner, S, 2017) |
| "Patients (n = 3589) with alcohol dependence receiving treatment in an alcohol clinical trial were primarily male (73." | 1.46 | Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials. ( Hallgren, KA; Heather, N; Kirouac, M; Maisto, SA; Montes, KS; Pearson, MR; Roos, CR; Wilson, AD; Witkiewitz, K, 2017) |
| "The treatment of alcohol dependence (AD) is a complex activity as the variables are numerous; however, those which must necessarily be taken into account are the type of AD, the internal comorbidities and the presence of any psychiatric comorbidity." | 1.43 | Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy. ( Borro, P; Leone, S; Testino, G, 2016) |
| "Acamprosate was applied subchronically for 2 days during withdrawal before the final behavioral test." | 1.42 | Effects of acamprosate on attentional set-shifting and cellular function in the prefrontal cortex of chronic alcohol-exposed mice. ( Carrasco, A; Hu, W; Kroener, S; Morris, B, 2015) |
| "Alcoholism is one of the most prevalent neuropsychiatric diseases, having an enormous health and socioeconomic impact." | 1.40 | Acamprosate produces its anti-relapse effects via calcium. ( Fischer, WN; Gallop, MA; Grindstaff, K; Jandeleit, B; Kiefer, F; Krstew, EV; Lawrence, AJ; Spanagel, R; Vengeliene, V; Zhang, X, 2014) |
| "Comorbidity of alcohol abuse and dependence with bipolar disorders is high." | 1.38 | Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.). ( Preuss, UW, 2012) |
| "Eligible adults with alcohol dependence were identified from a large US health plan and the IMS PharMetrics Integrated Database." | 1.37 | Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. ( Baser, O; Chalk, M; Gastfriend, DR; Rawson, R, 2011) |
| "Acamprosate is a drug intended to help prevent relapse among patients with alcohol dependence." | 1.34 | Acamprosate and primitive reflexes. ( Bankes, L; Brown, TM; Guzik, P, 2007) |
| "Acamprosate has a different mechanism of action than other drugs used for maintenance of abstinence from alcohol and is generally well tolerated." | 1.33 | Acamprosate campral for alcoholism. ( , 2005) |
| "Typically, patients with alcohol use disorders are only referred to psychosocial support (e." | 1.33 | The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. ( Leeman, RF; Starosta, AN; Volpicelli, JR, 2006) |
| " Chronic administration of acamprosate reduced both alcohol and water drinking during SIP, but did not significantly affect regulatory drinking or non-drinking measures." | 1.33 | Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. ( Escher, T; Mittleman, G, 2006) |
| "Being part of a study for alcohol dependence is known to increase the percentage of abstinent days." | 1.33 | Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention? ( Doggrell, SA, 2006) |
| "The acamprosate-treated group (n = 16) were given 666 mg t." | 1.32 | A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients. ( Feeney, A; Feldtkeller, B; Lingford-Hughes, A; Nutt, D; Weinstein, A, 2003) |
| "Treatment with acamprosate and psychosocial support, by promoting abstinence, improves the quality of life profile to levels comparable to those observed in healthy individuals." | 1.32 | Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. ( Landron, F; Lehert, P; Morgan, MY, 2004) |
| "Disulfiram has been shown to be most effective for patients who believe in its efficacy and remain compliant with the treatment." | 1.32 | [The pharmacologic treatment of the alcohol dependence]. ( Baltieri, DA; Castro, LA, 2004) |
| "All patients met DSM-IV criteria for alcohol dependence and the majority were socially disadvantaged." | 1.31 | Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? ( Connor, JP; Feeney, GF; McPherson, A; Tucker, J; Young, RM, 2002) |
| "Acamprosate was well tolerated by all patients." | 1.31 | An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome. ( Ansoms, C; Deckers, F; Lehert, P; Pelc, I; Potgieter, A, 2000) |
| "Alcohol relapse is a major problem in the treatment of alcohol abuse and alcoholism." | 1.31 | Central nervous system mechanisms in alcohol relapse. ( Le, AD; McBride, WJ; Noronha, A, 2002) |
| "Sleep-wake states were studied following withdrawal in 36 adult male wistar alcohol-dependent rats, after chronic administration of ethanol (10 g/kg/24 h) for 13 days." | 1.30 | Effects of muscimol or homotaurine on sleep-wake states in alcohol-dependent rats during withdrawal. ( Bajenaru, O; Dall'Ava-Santucci, J; Dinh-Xuan, AT; Emmanouilidis, E; Manicom, R; Poenaru, S; Rouhani, S; Tran, G, 1998) |
| "Acamprosate is a putative anticraving drug used to maintain abstinence in alcohol-dependent patients." | 1.30 | Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. ( al Qatari, M; Bouchenafa, O; Littleton, J, 1998) |
| "Acamprosate treatment did not modify blood ethanol levels." | 1.28 | Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. ( Daoust, M; DeWitte, P; Durbin, P; Gewiss, M; Heidbreder, C; Legrand, E; Tran, G, 1992) |
| "The effects of long term intake of dietary alcohol on myocardial glutathione metabolism and taurine content were studied in rats." | 1.27 | Effects of long term alcohol ingestion on glutathione metabolising enzymes and taurine contents in the myocardium of rats. ( Csanády, M; Edes, I; Kovács, K; Piros, G; Tóth, GK, 1986) |
| "This taurine pretreatment produced a 4-fold increase in liver taurine content." | 1.27 | Lowering of liver acetaldehyde but not ethanol concentrations by pretreatment with taurine in ethanol-loaded rats. ( Hobara, N; Nagashima, H; Watanabe, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (2.46) | 18.7374 |
| 1990's | 60 (16.39) | 18.2507 |
| 2000's | 169 (46.17) | 29.6817 |
| 2010's | 120 (32.79) | 24.3611 |
| 2020's | 8 (2.19) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, MF | 2 |
| Zhang, C | 1 |
| Wei, L | 1 |
| Zhang, L | 1 |
| Moon, I | 1 |
| Geske, JR | 3 |
| Skime, MK | 2 |
| Choi, DS | 3 |
| Biernacka, JM | 4 |
| Oesterle, TS | 1 |
| Frye, MA | 3 |
| Seppala, MD | 1 |
| Karpyak, VM | 4 |
| Li, H | 1 |
| Weinshilboum, RM | 2 |
| Konstantelos, N | 3 |
| Tourchian, N | 3 |
| McCormack, D | 3 |
| Lecce, P | 3 |
| Tadrous, M | 3 |
| Gomes, T | 4 |
| Stokłosa, I | 1 |
| Więckiewicz, G | 1 |
| Stokłosa, M | 1 |
| Piegza, M | 1 |
| Pudlo, R | 1 |
| Gorczyca, P | 1 |
| Ulenius, L | 1 |
| Adermark, L | 1 |
| Söderpalm, B | 2 |
| Ericson, M | 2 |
| Kirson, D | 1 |
| Oleata, CS | 1 |
| Roberto, M | 1 |
| Soyka, M | 16 |
| Rösner, S | 3 |
| Agabio, R | 2 |
| Balia, S | 1 |
| Gessa, GL | 2 |
| Pani, PP | 2 |
| Pal, H | 1 |
| Coombes, BJ | 1 |
| Batzler, A | 1 |
| Ho, AM | 1 |
| Frank, J | 3 |
| Hodgkinson, C | 1 |
| Skime, M | 1 |
| Colby, C | 1 |
| Zillich, L | 1 |
| Pozsonyiova, S | 1 |
| Kiefer, F | 20 |
| Rietschel, M | 3 |
| Weinshilboum, R | 1 |
| O'Malley, SS | 15 |
| Mann, K | 19 |
| Anton, R | 3 |
| Goldman, D | 3 |
| Thompson, A | 1 |
| Ashcroft, DM | 1 |
| Owens, L | 1 |
| van Staa, TP | 1 |
| Pirmohamed, M | 1 |
| Finlay, AK | 1 |
| Ellerbe, LS | 1 |
| Wong, JJ | 1 |
| Timko, C | 1 |
| Rubinsky, AD | 1 |
| Gupta, S | 1 |
| Bowe, TR | 1 |
| Burden, JL | 1 |
| Harris, AHS | 2 |
| Spithoff, S | 1 |
| Turner, S | 1 |
| Martins, D | 1 |
| Singh, S | 1 |
| Witkiewitz, K | 5 |
| Pearson, MR | 1 |
| Hallgren, KA | 1 |
| Maisto, SA | 1 |
| Roos, CR | 2 |
| Kirouac, M | 1 |
| Wilson, AD | 1 |
| Montes, KS | 1 |
| Heather, N | 1 |
| Nyhuis, PW | 1 |
| Niederhofer, E | 1 |
| Scherbaum, N | 3 |
| Schifano, F | 2 |
| Bonnet, U | 1 |
| Dembski, N | 1 |
| Niederhofer, A | 1 |
| Specka, M | 2 |
| Tenbergen, M | 1 |
| Klemperer, EM | 1 |
| Hughes, JR | 1 |
| Naud, S | 1 |
| Kranzler, HR | 7 |
| Gueorguieva, R | 4 |
| Wu, R | 4 |
| Krystal, JH | 4 |
| Donovan, D | 4 |
| DeSantis, SM | 5 |
| Bandyopadhyay, D | 2 |
| Baker, NL | 1 |
| Randall, PK | 2 |
| Anton, RF | 9 |
| Prisciandaro, JJ | 5 |
| O'Connor, PG | 2 |
| Krishnan-Sarin, S | 1 |
| O'Malley, S | 4 |
| Franck, J | 3 |
| Jayaram-Lindström, N | 2 |
| Litten, RZ | 9 |
| Falk, D | 4 |
| Ryan, M | 3 |
| Fertig, J | 4 |
| Castle, IJ | 1 |
| Chen, CM | 1 |
| Yi, HY | 1 |
| Kurokawa, K | 1 |
| Mizuno, K | 1 |
| Shibasaki, M | 1 |
| Higashioka, M | 1 |
| Oka, M | 2 |
| Hirouchi, M | 2 |
| Ohkuma, S | 1 |
| Spanagel, R | 13 |
| Vengeliene, V | 5 |
| Jandeleit, B | 1 |
| Fischer, WN | 1 |
| Grindstaff, K | 1 |
| Zhang, X | 2 |
| Gallop, MA | 1 |
| Krstew, EV | 1 |
| Lawrence, AJ | 3 |
| Bouzegaou, R | 1 |
| Daeppen, JB | 1 |
| Kraemer, KL | 1 |
| Müller, CA | 1 |
| Heinz, A | 5 |
| Heilig, M | 5 |
| Hsieh, YL | 1 |
| Yeh, YH | 1 |
| Lee, YT | 1 |
| Huang, CY | 1 |
| Zhu, H | 1 |
| Ohhara, T | 1 |
| Liang, J | 1 |
| Olsen, RW | 1 |
| Stout, RL | 1 |
| Braciszewski, JM | 1 |
| Subbaraman, MS | 2 |
| Kufahl, PR | 1 |
| Watterson, LR | 1 |
| Olive, MF | 3 |
| Oetzel, S | 1 |
| Jenkins, GD | 1 |
| Cunningham, JM | 1 |
| Rüegg, J | 1 |
| Kononenko, O | 1 |
| Leontovich, AA | 1 |
| Abulseoud, OA | 1 |
| Hall-Flavin, DK | 1 |
| Loukianova, LL | 1 |
| Schneekloth, TD | 1 |
| Nöthen, MM | 2 |
| Mann, KF | 1 |
| Schacht, JP | 1 |
| Book, SW | 2 |
| Testino, G | 2 |
| Leone, S | 2 |
| Borro, P | 2 |
| Icro Maremmani, AG | 1 |
| Bacciardi, S | 1 |
| Rovai, L | 1 |
| Rugani, F | 1 |
| Massimetti, E | 1 |
| Gazzarrini, D | 1 |
| Dell'Osso, L | 1 |
| Maremmani, I | 1 |
| Hulin, MW | 1 |
| Lawrence, MN | 1 |
| Amato, RJ | 1 |
| Weed, PF | 1 |
| Winsauer, PJ | 1 |
| Donoghue, K | 1 |
| Elzerbi, C | 1 |
| Saunders, R | 1 |
| Whittington, C | 1 |
| Pilling, S | 1 |
| Drummond, C | 1 |
| Higuchi, S | 1 |
| Mason, BJ | 15 |
| Saitz, R | 1 |
| Lieb, M | 1 |
| Hu, W | 1 |
| Morris, B | 1 |
| Carrasco, A | 1 |
| Kroener, S | 1 |
| Brower, KJ | 1 |
| Plosker, GL | 1 |
| Tsai, WM | 1 |
| Fucito, L | 1 |
| Zhang, H | 1 |
| Preti, A | 1 |
| Franconi, F | 1 |
| Ponizovskiy, PA | 1 |
| Gofman, AG | 1 |
| Shimizu, C | 1 |
| Oki, Y | 1 |
| Mitani, Y | 1 |
| Nakamura, T | 1 |
| Nabeshima, T | 1 |
| Stoddard, J | 1 |
| Zummo, J | 1 |
| Hoffmann, S | 2 |
| Pawlak, CR | 1 |
| McHugh, RK | 1 |
| Fitzmaurice, GM | 1 |
| Griffin, ML | 1 |
| Weiss, RD | 4 |
| Moyers, TB | 1 |
| Houck, J | 1 |
| Rice, SL | 1 |
| Longabaugh, R | 4 |
| Miller, WR | 5 |
| Matošić, A | 1 |
| Marušić, S | 1 |
| Vidrih, B | 1 |
| Kovak-Mufić, A | 1 |
| Cicin-Šain, L | 1 |
| Morley, KC | 2 |
| Logge, W | 2 |
| Pearson, SA | 2 |
| Baillie, A | 3 |
| Haber, PS | 3 |
| Salisbury-Afshar, E | 1 |
| Dunn, KE | 1 |
| Harrison, JA | 1 |
| Leoutsakos, JM | 1 |
| Han, D | 1 |
| Strain, EC | 1 |
| Hinton, DJ | 1 |
| Gunderson, LJ | 1 |
| Feeder, SE | 1 |
| Port, JD | 1 |
| Metrik, J | 1 |
| Patterson, D | 1 |
| Swift, R | 5 |
| Brewer, C | 1 |
| Streel, E | 1 |
| Skinner, M | 1 |
| Goh, ET | 1 |
| Morgan, MY | 4 |
| Ragia, G | 1 |
| Manolopoulos, VG | 1 |
| Littleton, J | 6 |
| Snyder, JL | 1 |
| Bowers, TG | 1 |
| Zweben, A | 3 |
| Pettinati, HM | 5 |
| Youngblood, M | 2 |
| Cox, CE | 1 |
| Mattson, ME | 4 |
| Gorroochurn, P | 1 |
| Ciraulo, D | 1 |
| Gupta, T | 1 |
| Syed, YM | 1 |
| Revis, AA | 1 |
| Miller, SA | 1 |
| Martinez, M | 1 |
| Cohn, KA | 1 |
| Demeyer, MR | 1 |
| Patel, KY | 1 |
| Brzezinska, WJ | 1 |
| Rhodes, JS | 1 |
| O'Brien, CP | 2 |
| Tek, C | 1 |
| Srihari, V | 1 |
| Tek, E | 1 |
| Mark, TL | 3 |
| Kassed, CA | 1 |
| Vandivort-Warren, R | 1 |
| Levit, KR | 1 |
| Zarkin, GA | 3 |
| Bray, JW | 3 |
| Aldridge, A | 1 |
| Mitra, D | 2 |
| Mills, MJ | 1 |
| Couper, DJ | 2 |
| Cisler, RA | 3 |
| Hosking, JD | 3 |
| Locastro, JS | 2 |
| Garbutt, JC | 4 |
| Mutschler, J | 2 |
| Diehl, A | 4 |
| Vollmert, C | 1 |
| Herre, H | 1 |
| Czachowski, CL | 1 |
| Delory, MJ | 1 |
| Smolka, M | 1 |
| Gann, H | 1 |
| Wellek, S | 2 |
| Gossai, D | 1 |
| Lau-Cam, CA | 1 |
| Colagiuri, B | 1 |
| Morley, K | 2 |
| Boakes, R | 1 |
| Haber, P | 2 |
| Hammarberg, A | 1 |
| Beck, O | 1 |
| Reid, MS | 1 |
| Thirthalli, J | 1 |
| Chand, PK | 1 |
| Leggio, L | 1 |
| Ray, LA | 4 |
| Kenna, GA | 2 |
| Swift, RM | 5 |
| Ooteman, W | 2 |
| Naassila, M | 1 |
| Koeter, MW | 4 |
| Verheul, R | 3 |
| Schippers, GM | 2 |
| Houchi, H | 1 |
| Daoust, M | 4 |
| van den Brink, W | 4 |
| Hanwella, R | 1 |
| de Silva, V | 1 |
| Oslin, DW | 1 |
| Heyser, CJ | 2 |
| Zahr, NM | 1 |
| Mayer, D | 1 |
| Rohlfing, T | 1 |
| Hasak, MP | 1 |
| Hsu, O | 1 |
| Vinco, S | 1 |
| Orduna, J | 1 |
| Luong, R | 1 |
| Sullivan, EV | 1 |
| Pfefferbaum, A | 1 |
| Abraham, AJ | 1 |
| Knudsen, HK | 2 |
| Rothrauff, TC | 1 |
| Roman, PM | 2 |
| Kennedy, WK | 1 |
| Leloux, M | 1 |
| Kutscher, EC | 1 |
| Price, PL | 1 |
| Morstad, AE | 1 |
| Carnahan, RM | 1 |
| Dunlap, LJ | 1 |
| Mills, M | 1 |
| Kivlahan, DR | 3 |
| McKay, JR | 1 |
| Latham, P | 1 |
| Tonigan, JS | 2 |
| Harris, AH | 1 |
| Bowe, T | 2 |
| Humphreys, KN | 1 |
| Yang, L | 1 |
| Latchoumycandane, C | 1 |
| McMullen, MR | 1 |
| Pratt, BT | 1 |
| Zhang, R | 1 |
| Papouchado, BG | 1 |
| Nagy, LE | 1 |
| Feldstein, AE | 1 |
| McIntyre, TM | 1 |
| Witt, SH | 1 |
| Richter, A | 1 |
| Treutlein, J | 1 |
| Lemenager, T | 2 |
| Cichon, S | 1 |
| Batra, A | 2 |
| Berner, M | 2 |
| Wodarz, N | 2 |
| Zimmermann, US | 2 |
| Wiedemann, K | 7 |
| Smolka, MN | 4 |
| Kobiella, A | 1 |
| Grosshans, M | 1 |
| Lehert, P | 12 |
| Greenfield, SF | 1 |
| Randall, CL | 2 |
| Leonardi-Essmann, F | 1 |
| Sommer, WH | 1 |
| Marston, HM | 1 |
| Wang, XQ | 2 |
| Liu, L | 2 |
| Mattson, M | 2 |
| Johnson, B | 1 |
| Stout, R | 1 |
| Umhau, JC | 2 |
| Momenan, R | 1 |
| Schwandt, ML | 2 |
| Singley, E | 2 |
| Lifshitz, M | 1 |
| Doty, L | 1 |
| Adams, LJ | 1 |
| Zhang, Y | 1 |
| Shen, J | 1 |
| George, DT | 2 |
| Hommer, D | 1 |
| Raj, YP | 1 |
| Wirtz, PW | 1 |
| Zywiak, WH | 1 |
| Capone, C | 1 |
| Kahler, CW | 1 |
| Rounsaville, BJ | 2 |
| Couper, D | 5 |
| Becker, U | 1 |
| Bendtsen, F | 1 |
| Zierau, F | 1 |
| Bowen, S | 1 |
| Donovan, DM | 3 |
| Usala, J | 1 |
| Geyer, C | 1 |
| Lieb, B | 2 |
| Kuhlmann, T | 2 |
| Frommann, N | 2 |
| Wobrock, T | 2 |
| Gaebel, W | 2 |
| Montejano, LB | 1 |
| Chalk, M | 2 |
| Gastfriend, DR | 3 |
| Cayley, WE | 1 |
| Hartzler, B | 1 |
| Villarroel, N | 1 |
| Wölwer, W | 1 |
| Jänner, M | 1 |
| Franke, PE | 1 |
| Falkai, P | 1 |
| Radermacher, M | 1 |
| Maier, W | 1 |
| Schütz, C | 2 |
| Ohmann, C | 1 |
| Burtscheidt, W | 1 |
| Brown, DG | 3 |
| Brady, KT | 4 |
| Tolliver, BK | 3 |
| Ralevski, E | 1 |
| O'Brien, E | 1 |
| Jane, JS | 1 |
| Dean, E | 1 |
| Dwan, R | 1 |
| Petrakis, I | 1 |
| Baser, O | 1 |
| Rawson, R | 1 |
| Campanella, S | 1 |
| Petit, G | 1 |
| Verbanck, P | 2 |
| Kornreich, C | 1 |
| Noel, X | 1 |
| Popova, S | 2 |
| Mohapatra, S | 2 |
| Patra, J | 2 |
| Duhig, A | 1 |
| Rehm, J | 2 |
| Schwappach, D | 1 |
| Godinho, A | 1 |
| Chiuzan, C | 1 |
| Yancey, JR | 1 |
| Lumbad, J | 1 |
| Petrov, I | 1 |
| Krogh, J | 1 |
| Nordentoft, M | 1 |
| Courtney, KE | 1 |
| Bujarski, S | 2 |
| Squeglia, LM | 1 |
| Hunter-Reel, D | 1 |
| Navarro, HJ | 1 |
| Shakeshaft, A | 1 |
| Doran, CM | 3 |
| Petrie, DJ | 1 |
| Miller, PM | 1 |
| Stewart, SH | 1 |
| Chen, J | 1 |
| Johnson, BA | 8 |
| O'Quigley, J | 1 |
| Isaac, M | 1 |
| Zhang, D | 1 |
| Fucito, LM | 1 |
| Park, A | 1 |
| Gulliver, SB | 1 |
| Gueorguieva, RV | 1 |
| Preuss, UW | 1 |
| Gahr, M | 1 |
| Kölle, MA | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Langosch, JM | 1 |
| Spiegelhalder, K | 1 |
| Jahnke, K | 1 |
| Feige, B | 1 |
| Regen, W | 1 |
| Kiemen, A | 1 |
| Hennig, J | 1 |
| Olbrich, HM | 1 |
| Witte, J | 1 |
| Bentley, K | 1 |
| Evins, AE | 1 |
| Clain, AJ | 1 |
| Baer, L | 1 |
| Pedrelli, P | 1 |
| Fava, M | 1 |
| Mischoulon, D | 1 |
| Berger, L | 1 |
| Fisher, M | 1 |
| Brondino, M | 1 |
| Bohn, M | 1 |
| Gwyther, R | 1 |
| Longo, L | 1 |
| Beier, N | 1 |
| Ford, A | 1 |
| Greco, J | 1 |
| Reinhard, I | 1 |
| Hermann, D | 1 |
| Lunny, K | 1 |
| Szponar, J | 1 |
| Kuźniar-Placek, J | 1 |
| Panasiuk, L | 1 |
| Kalk, NJ | 1 |
| Lingford-Hughes, AR | 1 |
| Ellerbe, L | 1 |
| Reeder, RN | 1 |
| Gordon, AJ | 1 |
| Hagedorn, H | 1 |
| Oliva, E | 1 |
| Lembke, A | 1 |
| Kivlahan, D | 1 |
| Trafton, JA | 1 |
| Blankson, KL | 1 |
| Thompson, AM | 1 |
| Ahrendt, DM | 1 |
| Patrick, V | 1 |
| Kim, JW | 1 |
| Lee, BC | 1 |
| Kang, TC | 1 |
| Choi, IG | 1 |
| Feeney, GF | 3 |
| Young, RM | 2 |
| Connor, JP | 3 |
| Tucker, J | 2 |
| McPherson, A | 2 |
| Goodman, AM | 2 |
| Dixon, RM | 1 |
| Hameed, MH | 1 |
| Hulot, T | 1 |
| Wesnes, K | 1 |
| Hunter, JA | 1 |
| Boyeson, MG | 1 |
| Pelc, I | 4 |
| Ansoms, C | 2 |
| Fischer, F | 2 |
| Fuchs, WJ | 2 |
| Landron, F | 5 |
| Pires Preto, AJ | 1 |
| Jahn, H | 6 |
| Tarnaske, T | 2 |
| Helwig, H | 2 |
| Briken, P | 1 |
| Holzbach, R | 1 |
| Kämpf, P | 1 |
| Stracke, R | 1 |
| Baehr, M | 1 |
| Naber, D | 2 |
| Rychlik, R | 2 |
| Siedentop, H | 1 |
| Pfeil, T | 2 |
| Daniel, D | 2 |
| Song, X | 1 |
| Bransberger, P | 1 |
| Poole, VH | 1 |
| Crosse, S | 1 |
| Niederhofer, H | 1 |
| Staffen, W | 1 |
| Kratzer, U | 1 |
| Schmidt, WJ | 1 |
| Ciraulo, DA | 2 |
| Roache, JD | 2 |
| Chambers, RA | 1 |
| Sarid-Segal, O | 1 |
| Weinstein, A | 1 |
| Feldtkeller, B | 1 |
| Feeney, A | 1 |
| Lingford-Hughes, A | 1 |
| Nutt, D | 1 |
| Fawcett, JE | 1 |
| Shakeshaft, AP | 1 |
| Shanahan, MD | 1 |
| Mattick, RP | 2 |
| Baltieri, DA | 3 |
| de Andrade, AG | 2 |
| TURNER, FP | 1 |
| BRUM, VC | 1 |
| PAQUETTE, WW | 1 |
| WELDEN, RB | 1 |
| Zornoza, T | 1 |
| Cano, MJ | 1 |
| Polache, A | 1 |
| Granero, L | 1 |
| Kim, SG | 1 |
| Han, BD | 1 |
| Park, JM | 1 |
| Kim, MJ | 1 |
| Stromberg, MF | 1 |
| Kiianmaa, K | 1 |
| Tiihonen, J | 1 |
| Hyytiä, P | 1 |
| Salaspuro, M | 1 |
| Chick, J | 3 |
| Zieglgänsberger, W | 5 |
| Boeijinga, PH | 1 |
| Parot, P | 4 |
| Soufflet, L | 1 |
| Danel, T | 2 |
| Gendre, I | 2 |
| Muzet, M | 3 |
| Demazières, A | 1 |
| Luthringer, R | 2 |
| Zimmerman, U | 1 |
| Spring, K | 1 |
| Koller, G | 1 |
| Holsboer, F | 1 |
| Bouza, C | 1 |
| Angeles, M | 1 |
| Magro, A | 1 |
| Muñoz, A | 1 |
| Amate, JM | 1 |
| Courtyn, J | 1 |
| Cornelissen, B | 1 |
| Oltenfreiter, R | 1 |
| Vandecapelle, M | 1 |
| Slegers, G | 1 |
| Strijckmans, K | 1 |
| Geerlings, PJ | 1 |
| Myrick, H | 2 |
| Kotlinska, J | 2 |
| Biala, G | 1 |
| Rafalski, P | 1 |
| Bochenski, M | 2 |
| Danysz, W | 2 |
| Pendyala, G | 1 |
| Abarca, C | 1 |
| Zghoul, T | 1 |
| Sanchis-Segura, C | 1 |
| Magnone, MC | 1 |
| Lascorz, J | 1 |
| Depner, M | 1 |
| Holzberg, D | 1 |
| Schreiber, S | 1 |
| Matsuda, F | 1 |
| Lathrop, M | 1 |
| Schumann, G | 1 |
| Albrecht, U | 1 |
| Castro, LA | 1 |
| Otte, C | 4 |
| Scott, LJ | 1 |
| Figgitt, DP | 1 |
| Keam, SJ | 1 |
| Waugh, J | 1 |
| De Witte, P | 9 |
| Koob, G | 1 |
| Demiralay, C | 1 |
| Wolf, K | 1 |
| Zalewska-Kaszubska, J | 2 |
| Cwiek, W | 1 |
| Dyr, W | 2 |
| Czarnecka, E | 2 |
| Cowen, MS | 1 |
| Adams, C | 1 |
| Kraehenbuehl, T | 1 |
| Boothby, LA | 1 |
| Doering, PL | 1 |
| Dahchour, A | 5 |
| Lallemand, F | 1 |
| Ward, RJ | 2 |
| Willenbring, ML | 1 |
| Lesch, OM | 4 |
| Berglund, M | 2 |
| Oroszi, G | 2 |
| Ait-Daoud, N | 3 |
| Buonopane, A | 1 |
| Petrakis, IL | 1 |
| Williams, SH | 1 |
| Egli, M | 2 |
| Sher, L | 1 |
| Reid, SC | 1 |
| Teesson, M | 2 |
| Sannibale, C | 2 |
| Matsuda, M | 1 |
| Duszynski, KM | 1 |
| Beilby, JJ | 1 |
| Chabac, S | 1 |
| Croissant, B | 1 |
| Klein, O | 2 |
| Zambrano, S | 1 |
| Nakovics, H | 2 |
| Jung, YC | 1 |
| Namkoong, K | 1 |
| Williams, LD | 1 |
| Starosta, AN | 1 |
| Leeman, RF | 1 |
| Volpicelli, JR | 1 |
| Escher, T | 1 |
| Mittleman, G | 1 |
| Batel, P | 1 |
| Balester-Mouret, S | 1 |
| Preskorn, SH | 1 |
| Borges, S | 1 |
| Flockhart, D | 1 |
| Staner, L | 1 |
| Boeijinga, P | 1 |
| Rabinowitz, AR | 1 |
| Doggrell, SA | 1 |
| Hillemacher, T | 1 |
| Kornhuber, J | 2 |
| Bleich, S | 1 |
| McD Young, R | 1 |
| Roesner, S | 1 |
| Ducharme, LJ | 1 |
| Mørland, J | 1 |
| Forcehimes, AA | 1 |
| Baer, JS | 1 |
| Tambour, S | 1 |
| Quertemont, E | 2 |
| Martin, DJ | 1 |
| Guzik, P | 1 |
| Bankes, L | 1 |
| Brown, TM | 1 |
| Heidbreder, CA | 1 |
| Andreoli, M | 1 |
| Marcon, C | 1 |
| Hutcheson, DM | 1 |
| Gardner, EL | 1 |
| Ashby, CR | 1 |
| Jiménez-Arriero, MA | 1 |
| Rubio, G | 1 |
| Han, DH | 1 |
| Lyool, IK | 1 |
| Sung, YH | 1 |
| Lee, SH | 1 |
| Renshaw, PF | 1 |
| Crean, R | 1 |
| Kuehn, BM | 1 |
| Margaron, H | 1 |
| Symons, M | 1 |
| Wiles, J | 1 |
| Górska, D | 1 |
| Leucht, S | 1 |
| Pettinati, H | 1 |
| Perney, P | 1 |
| Rigole, H | 1 |
| Blanc, F | 1 |
| Li, Z | 1 |
| Zharikova, A | 1 |
| Bastian, J | 1 |
| Esperon, L | 1 |
| Hebert, N | 1 |
| Mathes, C | 1 |
| Rowland, NE | 1 |
| Peris, J | 1 |
| Shea, CW | 1 |
| Blednov, YA | 1 |
| Harris, RA | 1 |
| Richardson, K | 1 |
| Reid, S | 1 |
| Weltman, M | 1 |
| Iwata, H | 1 |
| Matsuda, T | 1 |
| Lee, E | 1 |
| Yamagami, S | 1 |
| Baba, A | 1 |
| Paille, FM | 1 |
| Guelfi, JD | 1 |
| Perkins, AC | 1 |
| Royer, RJ | 1 |
| Steru, L | 2 |
| Ades, J | 1 |
| Lejoyeux, M | 2 |
| Ladewig, D | 1 |
| Knecht, T | 1 |
| Leher, P | 1 |
| Fendl, A | 1 |
| Whitworth, AB | 1 |
| Nimmerrichter, A | 1 |
| Oberbauer, H | 1 |
| Platz, T | 1 |
| Potgieter, A | 3 |
| Walter, H | 2 |
| Fleischhacker, WW | 1 |
| Sass, H | 2 |
| Allen, J | 1 |
| Lovinger, DM | 1 |
| Overstreet, DH | 1 |
| Kotter, G | 1 |
| Preuss, U | 3 |
| Wilde, MI | 1 |
| Wagstaff, AJ | 1 |
| Hölter, SM | 2 |
| Landgraf, R | 1 |
| Balldin, J | 1 |
| Bendtsen, P | 1 |
| Borg, S | 1 |
| Gustafsson, L | 1 |
| Halldin, J | 1 |
| Månsson, M | 1 |
| Nilsson, LH | 1 |
| Stolt, G | 1 |
| Willander, A | 1 |
| Le Bon, O | 1 |
| Gavrilovic, M | 1 |
| Lion, K | 1 |
| Moncrieff, J | 1 |
| Drummond, DC | 1 |
| Besson, J | 2 |
| Haddad, P | 1 |
| Daly, C | 1 |
| Poldrugo, F | 1 |
| Rouhani, S | 2 |
| Dall'Ava-Santucci, J | 1 |
| Bajenaru, O | 1 |
| Emmanouilidis, E | 2 |
| Tran, G | 5 |
| Manicom, R | 1 |
| Dinh-Xuan, AT | 1 |
| Poenaru, S | 2 |
| Aeby, F | 1 |
| Kasas, A | 1 |
| al Qatari, M | 1 |
| Bouchenafa, O | 1 |
| Wickelgren, I | 1 |
| Bolo, N | 1 |
| Nédélec, JF | 1 |
| Durbin, P | 3 |
| Macher, JP | 1 |
| Allen, JP | 2 |
| Gache, P | 1 |
| Siegrist, G | 1 |
| Kerai, MD | 1 |
| Waterfield, CJ | 1 |
| Kenyon, SH | 1 |
| Asker, DS | 1 |
| Timbrell, JA | 1 |
| Bonn, D | 1 |
| Aichmüller, C | 1 |
| Möller, HJ | 1 |
| Schädlich, PK | 1 |
| Brecht, JG | 1 |
| West, SL | 2 |
| Carey, TS | 2 |
| Lohr, KN | 2 |
| Crews, FT | 2 |
| Malerich, JA | 1 |
| Rueff, B | 1 |
| Mason, B | 1 |
| Farren, CK | 1 |
| Foster, RH | 1 |
| McClellan, KJ | 1 |
| Annemans, L | 1 |
| Vanoverbeke, N | 1 |
| Tecco, J | 1 |
| D'Hooghe, D | 1 |
| Oberpichler-Schwenk, H | 1 |
| Deckers, F | 1 |
| Kalb, C | 1 |
| Malcolm, R | 1 |
| Boening, JA | 1 |
| Wolffgramm, J | 1 |
| Narita, M | 1 |
| Sinclair, D | 1 |
| Wiesbeck, GA | 1 |
| Narahashi, T | 1 |
| Olausson, P | 1 |
| Engel, JA | 1 |
| Nordberg, A | 1 |
| Marszalec, W | 1 |
| Aistrup, GL | 1 |
| Schmidt, LG | 1 |
| Kalouti, U | 1 |
| Smolka And, M | 1 |
| Hedlund, L | 1 |
| Bean, P | 1 |
| Lux, LJ | 1 |
| Jackman, AM | 1 |
| Tolleson-Rinehart, S | 1 |
| Gordon, SM | 1 |
| Paschen, B | 1 |
| Kirchhoff, D | 1 |
| Kilburg, A | 1 |
| Korpi, E | 1 |
| Seppälä, T | 1 |
| Van Kirk, J | 1 |
| Yarborough, WH | 1 |
| Rimondini, R | 1 |
| Arlinde, C | 1 |
| Sommer, W | 1 |
| Martinez, J | 1 |
| Ball, D | 1 |
| Marshall, EJ | 1 |
| Schuetz, C | 1 |
| McBride, WJ | 1 |
| Le, AD | 1 |
| Noronha, A | 1 |
| Koob, GF | 1 |
| Siggins, GR | 1 |
| Riebenfeld, D | 1 |
| Fideli, LP | 1 |
| Graham, R | 1 |
| Wodak, AD | 1 |
| Whelan, G | 1 |
| Ikeda, H | 1 |
| Potgieter, AS | 1 |
| Opsomer, L | 2 |
| Payan, C | 1 |
| Castresana, A | 1 |
| Soulairac, A | 1 |
| Legrand, E | 1 |
| Gewiss, M | 2 |
| Heidbreder, C | 2 |
| DeWitte, P | 1 |
| Moore, N | 2 |
| Libert, C | 2 |
| Lhuintre, JP | 2 |
| Langrenon, S | 1 |
| Ladure, P | 1 |
| Boismare, F | 1 |
| Moore, ND | 1 |
| Chretien, P | 1 |
| Saligaut, C | 1 |
| Bosimare, F | 1 |
| Hillemand, B | 1 |
| Liskow, BI | 1 |
| Goodwin, DW | 1 |
| Durlach, J | 1 |
| Rinjard, P | 1 |
| Sprince, H | 1 |
| Smith, GG | 1 |
| Mårtensson, J | 1 |
| Bolin, T | 1 |
| Edes, I | 1 |
| Piros, G | 1 |
| Tóth, GK | 1 |
| Csanády, M | 1 |
| Kovács, K | 1 |
| Watanabe, A | 1 |
| Hobara, N | 1 |
| Nagashima, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Developing and Implementing an Online Relapse Prevention Psychotherapy Program for Patients With Alcohol Use Disorder[NCT05579210] | 60 participants (Anticipated) | Interventional | 2022-10-01 | Recruiting | |||
| Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial[NCT02771925] | Phase 4 | 25 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to poor compliance of patients in the study.) | ||
| COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions[NCT00006206] | Phase 3 | 1,375 participants | Interventional | 1997-08-31 | Completed | ||
| Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal[NCT00106106] | Phase 2 | 56 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Randomized Controlled Trial on the Effectiveness of Immediate Versus Delayed Access to Hospital-based Addiction Services[NCT01934751] | 124 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | |||
| Impact of Alcohol Consumption of the General Population Who Visited Primary Health Care Centers on the Use of Health Care Resources in Catalonia.[NCT02343874] | 1,911,771 participants (Actual) | Observational | 2012-12-31 | Completed | |||
| A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence[NCT00452543] | Phase 4 | 23 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study[NCT00381043] | Phase 4 | 100 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Individually Adapted Therapy of Alcoholism: Clinical Studies[NCT00317031] | Phase 4 | 435 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Assessment and Treatment of People With Alcohol Drinking Problems[NCT00106093] | 1,192 participants (Actual) | Observational | 2005-03-16 | Completed | |||
| A Multi-site Study to Disseminate and Evaluate Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers[NCT01638377] | Phase 4 | 2 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to Recruitment proved to be extremely difficult.) | ||
| Treatment of Patients With Alcoholism and Attention Deficit Disorder[NCT00261872] | Phase 4 | 100 participants | Interventional | 2005-12-01 | Completed | ||
| Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial[NCT00590642] | 30 participants (Anticipated) | Observational | 2006-04-30 | Completed | |||
| Open-Label Pilot Study of Long-Acting Injectable Naltrexone Treatment for Cannabis Dependence[NCT02088177] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study[NCT01187511] | Phase 2 | 44 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics[NCT01227980] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics[NCT00605904] | Phase 2 | 37 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence[NCT00570388] | 120 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | |||
| Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy[NCT01087736] | Phase 4 | 30 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence[NCT00762710] | Phase 2 | 92 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Participatory System Dynamics vs Audit and Feedback: A Cluster Randomized Trial of Mechanisms of Implementation Change to Expand Reach of Evidence-based Addiction and Mental Health Care[NCT04356274] | 720 participants (Anticipated) | Interventional | 2019-02-01 | Enrolling by invitation | |||
| Improving Alcohol Use Disorder Treatment for Gender Minority Populations[NCT05070793] | 20 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 25
| Intervention | Ratio of glutamate to creatine (Mean) |
|---|---|
| Placebo | 1.350375 |
| Acamprosate | 1.166667 |
The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 4
| Intervention | Ratio of glutamate to creatine (Mean) |
|---|---|
| Placebo | 1.256772 |
| Acamprosate | 1.294178 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Scores on the HAM-D-17 typically fall into the following ranges: a) Not depressed: 0-7; b) Mildly depressed: 7-15; c) Moderately depressed: 15-25; d) Severely depressed: over 25. A decrease of 50% or more in the Hamilton-D score is considered to be a positive response to treatment, while a score of 7 or less is considered typical of remission. We measure the change in total score from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | -5.6 |
| Escitalopram Plus Placebo | -7.8 |
The TLFB assesses recent drinking behavior. On the TLFB, clients retrospectively estimate their daily alcohol consumption in standard drinks over a time period ranging from 7 days to 24 months prior to the interview, and thus the measure provides quantitative estimates of alcohol use. One standard drink on the TLFB was defined as: 12 oz beer (5% alcohol by volume), 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Drinking days (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | 61 |
| Escitalopram Plus Placebo | 61 |
Total Drinks Consumed per Drinking Day on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Drinks consumed per drinking day (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | 4 |
| Escitalopram Plus Placebo | 4 |
Total Drinks Consumed per Week on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Drinks consumed per week (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | 15 |
| Escitalopram Plus Placebo | 15 |
% of individuals with evidence for 80% compliance with medication based on returned blister packs and weekly diaries. (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 93.3 |
| 2 - Sugar Pill - Placebo | 91.6 |
Percentage of participants who dropped out of study by drug condition (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 21.5 |
| 2 - Sugar Pill - Placebo | 16.3 |
% of Heavy drinking days (5 or more drinks/d for a man or 4 or more drinks/d for a woman) over the 12 weeks of the trial. (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of heavy drinking days (Mean) |
|---|---|
| 1- Acamprosate | 15.8 |
| 2 - Sugar Pill - Placebo | 18.4 |
Range of overall severity of illness: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill (NCT00381043)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| 1- Acamprosate | 2.3 |
| 2 - Sugar Pill - Placebo | 2.4 |
%Days without any alcohol consumption over the treatment period (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| 1- Acamprosate | 40.7 |
| 2 - Sugar Pill - Placebo | 41.6 |
% of subjects with no drinking during the 12 week treatment trial (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 5.9 |
| 2 - Sugar Pill - Placebo | 19.1 |
Number of individuals retained in the trial by acamprosate vs placebo group (NCT00381043)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| 1- Acamprosate | 39 |
| 2 - Sugar Pill - Placebo | 41 |
Change in marijuana use, as measured by comparing the mean number of self reported days of marijuana use per week in the final study week, which will be week 8 or earlier if the participant discontinues as compared to the mean number of self reported days of marijuana use in week 1 (NCT02088177)
Timeframe: Weeks 1 - 8
| Intervention | days (Mean) |
|---|---|
| Open Label Group | -1.7 |
The number of participants who accept the second injection at week 5 will be used as one measure of tolerability. (NCT02088177)
Timeframe: Weeks 1 - 5
| Intervention | Participants (Count of Participants) |
|---|---|
| Open Label Group | 6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.6932 |
| Placebo | 14.6126 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.7646 |
| Placebo | 10.413 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.4075 |
| Placebo | 13.0412 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.9789 |
| Placebo | 15.946 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.9075 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 11.6603 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.9075 |
| Placebo | 13.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.1376 |
| Placebo | 13.1086 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.7805 |
| Placebo | 10.6194 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.7091 |
| Placebo | 13.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.3519 |
| Placebo | 12.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 14.1376 |
| Placebo | 16.9051 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.2805 |
| Placebo | 12.0956 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.2091 |
| Placebo | 10.3813 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.1376 |
| Placebo | 10.0004 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 100 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.977 |
| Placebo | 12.0475 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 15.1645 |
| Placebo | 12.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 20 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 18.4145 |
| Placebo | 15.2497 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 40 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 20.352 |
| Placebo | 18.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 70 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.7895 |
| Placebo | 13.0592 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.8582 |
| Placebo | 8.7076 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.4777 |
| Placebo | 7.041 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.5443 |
| Placebo | 6.6122 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.011 |
| Placebo | 5.4219 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.611 |
| Placebo | 5.7835 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.3112 |
| Placebo | 5.1362 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.2231 |
| Placebo | 4.5648 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2365 |
| Placebo | 4.2791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6777 |
| Placebo | 5.9457 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6078 |
| Placebo | 6.66 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 10.002 |
| Placebo | 8.7759 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.3187 |
| Placebo | 6.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.6521 |
| Placebo | 8.0633 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.0521 |
| Placebo | 6.5855 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.0521 |
| Placebo | 5.9353 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8092 |
| Placebo | 4.9188 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.149 |
| Placebo | 4.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8071 |
| Placebo | 4.2045 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.2521 |
| Placebo | 7.1569 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6366 |
| Placebo | 6.9188 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.5572 |
| Placebo | 12.2152 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.7 |
| Placebo | 8.8468 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.7 |
| Placebo | 7.3205 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.2715 |
| Placebo | 6.9521 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2715 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.6286 |
| Placebo | 6.6363 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.6083 |
| Placebo | 6.5836 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.7666 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.9858 |
| Placebo | 9.7942 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.1286 |
| Placebo | 8.7942 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.6 |
| Placebo | 12.9 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.7 |
| Placebo | 10.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.5 |
| Placebo | 11.8 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15 |
| Placebo | 12.1 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 18.7 |
| Placebo | 14.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 12.3 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.5 |
| Placebo | 12 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.8 |
| Placebo | 12.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.9 |
| Placebo | 10.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15.3 |
| Placebo | 12.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 17.8 |
| Placebo | 14.4 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.3 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.6 |
| Placebo | 11.2 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.460 |
| Placebo | 5.416 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 1.704 |
| Placebo | 1.766 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.613 |
| Placebo | 3.606 |
"Alcohol consumption was assessed at baseline and weekly during the treatment phase (12 weeks) using the Time Line Follow Back (TLFB) interview which yields number of days of alcohol use (DD).~DD: day on which alcohol was consumed Standard alcoholic drink defined as containing 13.6 g of pure alcohol." (NCT01087736)
Timeframe: Weekly, weeks 1-12, average
| Intervention | percent days in a week (Mean) |
|---|---|
| Topiramate | 19.5 |
| Placebo | 39.7 |
The average PTSD symptom severity score during treatment (weeks 4, 8, 12). The PTSD Checklist (PCL) is a self-report measure of the 17 DSM-IV symptoms of PTSD. Respondents rate on a scale from 1 (not at all) to 5 (extremely) how much they were bothered by each symptom in the past month. A total symptom severity score (range = 17 - 85) can be obtained by summing the scores from the 17 items, with higher scores indicating greater severity of PTSD symptoms. Mean scores may be calculated for subscales of intrusion (range 5-25), avoidance (range 7-35), and arousal (range 5-25). (NCT01087736)
Timeframe: Weeks 4, 8, 12
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PCL Total Score (Weeks 1-12 Average) | PCL-B Intrusion (Weeks 1-12 Average) | PCL-C Avoidance (Weeks 1-12 Average) | PCL-D Arousal (Weeks 1-12 Average) | |
| Placebo | 49.0 | 14.3 | 19.9 | 14.9 |
| Topiramate | 42.3 | 12.3 | 17.6 | 12.4 |
At the baseline and final medication visits, the Form 90 (19) was used to assess alcohol and drug use for the preceding 90-day period (NCT00762710)
Timeframe: 12 weeks
| Intervention | percentage of days heavy drinking (Mean) | |
|---|---|---|
| Baseline % Days Heavy Drinking | Final medication week % Days Heavy Drinking | |
| Placebo | 66.5 | 22.6 |
| Prazosin | 71.8 | 11.4 |
125 reviews available for taurine and Alcohol Abuse
| Article | Year |
|---|---|
Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Pharmaceutical Preparations; Public | 2023 |
[Pharmacotherapy of alcohol withdrawal: update and new developments].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone; Narcotic Antagonists; Taur | 2021 |
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.
Topics: Alcohol Deterrents; Alcoholism; Female; Genome-Wide Association Study; Humans; Male; Naltrexone; Nar | 2021 |
Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Randomiz | 2018 |
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Disulfiram; Humans; Naltrexone; Taurine | 2018 |
Medications for unhealthy alcohol use: across the spectrum.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; N | 2011 |
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain Chemistry; Disulfiram; Humans; Naltrexone; Narcot | 2008 |
Pharmacotherapy for alcohol dependence: status of current treatments.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Humans; Multicent | 2013 |
Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Biomedical Research; Drug Industry; Health Services Nee | 2014 |
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; N | 2013 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; | 2013 |
A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bayes Theorem; Humans; Naltrexone; Randomized Controlle | 2014 |
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; | 2014 |
The development of acamprosate as a treatment against alcohol relapse.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Humans; Recurrence; Taurine | 2014 |
Pharmacologic treatment of alcoholism.
Topics: Acamprosate; Alcoholism; Animals; Brain; Humans; Naltrexone; Nerve Net; Neuroimaging; Pharmacogeneti | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking | 2014 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Europe; Female; Global Health; Humans; Male; Mid | 2015 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Na | 2015 |
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amines; Anti-Anxiety Agents; Anticonvulsants; Antipsych | 2015 |
Acamprosate: A Review of Its Use in Alcohol Dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Interac | 2015 |
Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Benzodiaz | 2016 |
[Depression in alcohol addicted patients].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder | 2015 |
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain; Disulfiram; Dopamine; gamma-Aminobutyric Acid; G | 2016 |
Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bioethical Issues; Disulfiram; Humans; Naltrexone; Taur | 2017 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Huma | 2017 |
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Pharmacogenetics; Polym | 2017 |
Acamprosate: recent findings and future research directions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; gamma-Aminobutyric Acid; Glu | 2008 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Follow-Up Studies; Hum | 2008 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations | 2009 |
[Recent results in relaps prevention of alcoholism with Disulfiram].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Aldehyde Dehydrogenase; Combined Modality Therapy; Disu | 2008 |
The implications of medication development in the treatment of substance use disorders in developing countries.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Comorbidity; Developing Countries; Disul | 2009 |
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy | 2008 |
The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cognition; Diarrhea; Disease Models, Animal; D | 2010 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Randomized Controlled Trials as Topic; Taurine | 2010 |
Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Bra | 2010 |
Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Drug Delivery Systems; Human | 2010 |
Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Medication Adherence; Midd | 2010 |
How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognition; Humans; Naltrexone; Psychotherapy; Taurine | 2011 |
Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Randomized Controlled Tria | 2012 |
A literature review of cost-benefit analyses for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Belgium; Cost-Benefit Analysis; Humans; Psychotherapy; | 2011 |
Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
Topics: Acamprosate; Alcoholism; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Naltrexone; Taurin | 2012 |
Opioid antagonists for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Evidence-Based Medicine; Hum | 2011 |
[Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Evidence-Based Medicine; Humans; Naltrexone | 2011 |
Medical treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Anta | 2011 |
[Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Middle Aged; | 2013 |
[The patient with an alcohol abuse problem family doctor practice].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Family Practice; Humans; Poland; Practice P | 2012 |
The clinical pharmacology of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Humans; Rodentia; Secondary Prevention; Substa | 2014 |
Energy drinks: what teenagers (and their doctors) should know.
Topics: Adolescent; Advertising; Alcoholism; Caffeine; Energy Drinks; Humans; Marketing; Panax; Paullinia; T | 2013 |
The current situation of treatment systems for alcoholism in Korea.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Benzodiazepines; Humans; Naltrexone; Psychotherapy; Rep | 2013 |
Interactions between taurine and ethanol in the central nervous system.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior; Behavior, Animal; Central Nervous Sy | 2002 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Double-Blind Method; Humans; Multicenter St | 2003 |
Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Evidenc | 2003 |
Pharmacology of acamprosate: an overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Biological Availability; Humans; Intestinal Ab | 2003 |
The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.
Topics: Acamprosate; Alcoholism; Confidence Intervals; Humans; Randomized Controlled Trials as Topic; Taurin | 2004 |
[Neural basis of alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Dopamine; Ethanol; Humans; Narcotic Antagonist | 2003 |
[Drug therapy of alcohol dependence--a critical review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic | 2003 |
Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Brain; Humans; Naltrexone; N | 2003 |
Current pharmacotherapies of alcoholism: a U.S. perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Drug Therapy | 2003 |
Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Europe; Humans; Meta-Analysis as Topic; Naltrexone; Nar | 2003 |
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Co | 2004 |
Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
Topics: Acamprosate; Adult; Age Factors; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anxiety; Do | 2005 |
Recent advances in the pharmacotherapy of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Fructose; Hu | 2004 |
[Advances in the treatment of alcohol dependence: pharmacological relapse prevention].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Ethanol; Humans; Randomized Controlled Trials as Topic; | 2003 |
Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Humans; Taurine | 2005 |
Acamprosate (Campral) for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Costs; Drug Interactions; Humans; Randomized Contr | 2005 |
Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.
Topics: Acamprosate; Alcoholism; Animals; Drug Interactions; Ethanol; Excitatory Amino Acids; Humans; Models | 2005 |
Acamprosate for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Diarrhea; Humans; Meta-Analysis as Topic; Molecular Str | 2005 |
Acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Taurine; Treatment Outcome | 2005 |
Combining treatments for alcoholism: why and how?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Hu | 2005 |
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Topics: Acamprosate; Alcohol Dehydrogenase; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Thera | 2005 |
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Humans; Naltrexone; Narcotic | 2005 |
Pharmacotherapy of alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Comorb | 2005 |
Medications for treating alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dos | 2005 |
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Anim | 2005 |
Alcoholism and suicidal behavior: a clinical overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans; | 2006 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alzheimer Disease; Brain; Dopamine Agents; Humans; Mema | 2006 |
Choosing the right medication for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Choice Behavior; Cognitive Behavioral Therapy; Combined | 2006 |
[Neurobiological mechanisms and pharmacological treatment options for alcohol craving].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Humans; Naltrexone; Narcotic Antag | 2007 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Ani | 2006 |
Trends in the adoption of medications for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Longitudinal Studies; Naltrexone; N | 2006 |
[Pharmacological relapse prevention in alcohol and tobacco dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Di | 2007 |
Preclinical and clinical pharmacology of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Dopamine; GABA Modulators; Glutami | 2007 |
Therapeutics for alcoholism: what's the future?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Cannabinoid Receptor Antagonists; Human | 2007 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; R | 2008 |
Acamprosate in the treatment of alcohol dependence: clinical and economic considerations.
Topics: Acamprosate; Alcoholism; Humans; Randomized Controlled Trials as Topic; Taurine | 2007 |
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Middle Aged; Naltrexon | 2008 |
[Alcohol dependence: diagnosis and treatment].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Motiv | 2008 |
Acamprosate in alcohol dependence: how does it work?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Mo | 1995 |
Clinical evaluation of acamprosate to reduce alcohol intake.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Controlled Clinical Trials as Topic; Double-Blind Method; | 1993 |
Acamprosate as an aid in the treatment of alcoholism.
Topics: Acamprosate; Alcoholism; gamma-Aminobutyric Acid; Humans; Taurine | 1995 |
The pharmacological treatment of alcohol dependence: needs and possibilities.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Germany; Humans; Patient Care Team; Psychotropic Drugs; | 1996 |
Subtypes of alcoholism and their role in therapy.
Topics: Acamprosate; Alcoholism; Humans; Taurine; Treatment Outcome | 1996 |
Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991.
Topics: Acamprosate; Alcohol Withdrawal Delirium; Alcoholism; Anxiety Disorders; Comorbidity; Depressive Dis | 1996 |
[Pharmacotherapy of alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Dopamine Agents; Hum | 1996 |
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans | 1997 |
The pharmacological treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfi | 1997 |
Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Drug Evaluation, Pre | 1997 |
[Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Narcotic Antagonists; Randomized Controlled Tri | 1997 |
Acamprosate for alcohol dependence?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Controlled Clinical Trials as Topic; Humans; Substance | 1997 |
[Alcoholism: relapse prevention].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Humans; Medical History Taki | 1997 |
[New drugs in the treatment of alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Brain; Humans; Receptors, | 1997 |
Advances in development of medications for alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Drug Therapy, Combination; Human | 1998 |
The pharmacological treatment of alcohol dependence: needs and possibilities.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Humans; Recurrence; Taurine | 1996 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl | 1999 |
[Prevention of recurrent alcoholism with acamprosate. Neurobiological principles and clinical results].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Clinical Trials as Topic; Humans; Recep | 1999 |
Pharmacological treatment of alcohol dependence: a review of the evidence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Lithium; Naltrexone; Narcoti | 1999 |
[Evaluation of drug treatment of primary alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Self | 1999 |
Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Eth | 2000 |
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Drug Therapy, Combination; Humans; Naltrexone; | 2000 |
Medications to treat alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Calcium Channel Blockers; Dopamine Antagonists; Drug Th | 1999 |
Taurine - monograph.
Topics: Alcoholism; Alzheimer Disease; Animals; Cardiovascular Diseases; Cystic Fibrosis; Diabetes Mellitus; | 2001 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carb | 2001 |
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Anim | 2001 |
Mechanisms of alcohol-nicotine interactions: alcoholics versus smokers.
Topics: Acamprosate; Acetylcholine; Alcohol Deterrents; Alcoholism; Animals; Central Nervous System Depressa | 2001 |
Pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Health Policy; Humans; Lithium; Naltrexone; | 1999 |
[Alcohol--mechanism of action, interactions and treatment of alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Ethanol; Humans; Naltrexone; Narcoti | 1998 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; | 2001 |
Pharmacologic approaches to the management of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Clinical Trials as Topic; Disulfir | 2001 |
Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Ambulatory Care; Behavior, Addictive; Controlled Clinic | 2001 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Humans; Substance Withdrawal Syndrom | 2002 |
[Long-term treatment of alcohol dependance].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Disulfiram; Family Therapy; | 2002 |
New pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Disulfiram; Humans; Naltrexone; Narcotic Ant | 2002 |
Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review.
Topics: Alcohol Deterrents; Alcoholic Intoxication; Alcoholism; Antidepressive Agents, Tricyclic; Bromocript | 1987 |
83 trials available for taurine and Alcohol Abuse
| Article | Year |
|---|---|
Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine Outpatient Treatment of Alcohol-Dependent Patients.
Topics: Acamprosate; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disulfiram; Female | 2018 |
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; | 2013 |
What happens when people discontinue taking medications? Lessons from COMBINE.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Mod | 2014 |
Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study).
Topics: Acamprosate; Adult; Aged; Alcoholism; Double-Blind Method; Ethanol; Female; Humans; Japan; Long-Term | 2015 |
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Body Mass Index; Decision Trees; Double-Blind Me | 2015 |
Therapist empathy, combined behavioral intervention, and alcohol outcomes in the COMBINE research project.
Topics: Acamprosate; Adaptation, Psychological; Affect; Alcohol Deterrents; Alcoholism; Behavior Therapy; Co | 2016 |
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexo | 2017 |
Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence.
Topics: Acamprosate; Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Double-Bli | 2017 |
Relationship between medication adherence and treatment outcomes: the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Fem | 2008 |
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cos | 2008 |
Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Thera | 2008 |
Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Dopamine Agents; Doub | 2009 |
The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Analysis of Variance; Behavior, Addictive; Body | 2009 |
Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Blood Glucos | 2009 |
Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cues; Female; Genotype; Humans; Male; Middle Age | 2009 |
Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Black or African American; Com | 2009 |
[Impact of functional social support for abstinence after inpatient detoxification].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexam | 2010 |
Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Prognosis; Socia | 2010 |
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Fema | 2011 |
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Male; | 2011 |
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Comb | 2011 |
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.
Topics: Acamprosate; Adrenergic alpha-2 Receptor Antagonists; Adult; Alcohol Deterrents; Alcohol-Induced Dis | 2011 |
Marked reduction of heavy drinking did not reduce nicotine use over 1 year in a clinical sample of alcohol-dependent patients.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Ethanol | 2011 |
Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Behavior Th | 2011 |
The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cou | 2011 |
Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Bipolar Disorder; Comorbidity | 2011 |
Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognition; Double-Blind Method; Femal | 2011 |
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Mod | 2012 |
Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Ad | 2012 |
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Thera | 2012 |
A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcoholism; Bipolar Disorder; Double-Blind Method; F | 2012 |
The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Alcoholism; Cost-Benefit Analysis; Female; General Practitioners; Hu | 2012 |
Trajectory analyses in alcohol treatment research.
Topics: Acamprosate; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Algorithms; Behavior Th | 2012 |
Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Com | 2012 |
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality T | 2012 |
The impact of acamprosate on cue reactivity in alcohol dependent individuals: a functional magnetic resonance imaging study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Brain; Cues; Female; Gyrus Cinguli; Humans; Magn | 2012 |
A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder.
Topics: Acamprosate; Adult; Alcoholism; Citalopram; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry) | 2012 |
Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Family Practice; Female; Fo | 2013 |
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Counseling; Disease-Free Surviv | 2013 |
The effects of drinking goal on treatment outcome for alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; | 2013 |
A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
Topics: Acamprosate; Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brain; Cognition; Double-Blind Metho | 2002 |
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
Topics: Acamprosate; Alcoholism; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; | 2003 |
Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cohort Studies; Combined Modality Therapy; Cost- | 2003 |
Acamprosate and its efficacy in treating alcohol dependent adolescents.
Topics: Acamprosate; Adolescent; Adolescent Behavior; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Me | 2003 |
Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
Topics: Acamprosate; Adult; Alcoholism; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind M | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; | 2003 |
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Fe | 2003 |
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Fe | 2003 |
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Fe | 2003 |
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Fe | 2003 |
Efficacy of acamprosate in the treatment of alcohol-dependent outpatients.
Topics: Acamprosate; Adolescent; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Double-Blind Method | 2003 |
Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting.
Topics: Acamprosate; Adolescent; Adult; Alcoholism; Ambulatory Care; Analysis of Variance; Chi-Square Distri | 2004 |
Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Arousal; Cerebral Cortex; Double-Blind Method; E | 2004 |
Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate.
Topics: Acamprosate; Administration, Oral; Adrenocorticotropic Hormone; Adult; Alcohol Deterrents; Alcoholis | 2004 |
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; | 2005 |
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Leptin; Mal | 2005 |
The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle A | 2005 |
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Topics: Acamprosate; Adrenocorticotropic Hormone; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method | 2006 |
Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Male; Motiv | 2006 |
A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Anticonvulsants; Carbamazepine; Female; Humans; | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle A | 2006 |
Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Central Nervous System Depressants; Compulsive P | 2006 |
Psychometrics of the Drinker Inventory of Consequences (DrInC).
Topics: Acamprosate; Alcoholism; Combined Modality Therapy; Factor Analysis, Statistical; Follow-Up Studies; | 2007 |
Measuring economic outcomes of alcohol treatment using the Economic Form 90.
Topics: Absenteeism; Acamprosate; Accidents, Traffic; Adult; Alcohol Deterrents; Alcoholism; Behavior Therap | 2007 |
The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Topics: Acamprosate; Affect; Alcohol Deterrents; Alcoholism; Autonomic Nervous System; Cues; Double-Blind Me | 2007 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Mod | 2008 |
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Topics: Acamprosate; Adult; Alcoholism; Alleles; Amino Acid Substitution; Asparagine; Aspartic Acid; Cogniti | 2008 |
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Female; Humans; Male; Middl | 2008 |
Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcoholism; Combined Modality Therapy; Dose-Response Relations | 1995 |
[Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients].
Topics: Acamprosate; Adult; Alcoholism; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Ag | 1993 |
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
Topics: Acamprosate; Adult; Alcoholism; Double-Blind Method; Ethanol; Female; Follow-Up Studies; Humans; Mal | 1996 |
Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Follow-Up Studi | 1996 |
Subtypes of alcoholism and their role in therapy.
Topics: Acamprosate; Alcoholism; Humans; Taurine; Treatment Outcome | 1996 |
Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism--preliminary data.
Topics: Acamprosate; Adult; Aged; Alcoholism; Double-Blind Method; Drug Tolerance; Female; gamma-Glutamyltra | 1994 |
Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Diarrhea; Dose-Response Relati | 1997 |
Acamprosate treatment in a long-term community-based alcohol rehabilitation programme.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Community Mental Health Servic | 1997 |
Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Double-Blind Method; Drug Therapy, C | 1998 |
Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Automobile Driving; Humans; Male; Middle Aged; P | 1998 |
Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Belgium; Humans; Markov Chains; Models, Economic; Place | 2000 |
[Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Budgets; Cohort Studies; Cost-Benefit Analysis; | 2001 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; | 2001 |
Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; G | 2002 |
[Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Female; Humans; Male; | 2002 |
Acamprosate appears to decrease alcohol intake in weaned alcoholics.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; D | 1990 |
Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Indices; | 1985 |
160 other studies available for taurine and Alcohol Abuse
| Article | Year |
|---|---|
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ethanol; Genome-Wide Association Stud | 2022 |
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine | 2023 |
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine | 2023 |
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine | 2023 |
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine | 2023 |
Energy drink constituents (caffeine and taurine) selectively potentiate ethanol-induced locomotion in mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Caffeine; Dopamine; Energy Drinks; Ethanol; Locomotion; Male; | 2019 |
Taurine Suppression of Central Amygdala GABAergic Inhibitory Signaling via Glycine Receptors Is Disrupted in Alcohol Dependence.
Topics: Alcoholism; Animals; Central Amygdaloid Nucleus; Ethanol; GABAergic Neurons; Inhalation Exposure; In | 2020 |
Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Retrospective Studies; Taurine | 2021 |
In recently detoxified alcohol-dependent adults, acamprosate increases abstinence maintenance and reduces dropout.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ethanol; Humans; Taurine | 2021 |
Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Cohort Studies; Disulfiram; Fe | 2017 |
Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Interviews as Topic; Male; Naltrexone; | 2017 |
First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Humans; Insurance, Pharmaceutical | 2017 |
Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Dri | 2017 |
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Fem | 2013 |
Acamprosate suppresses ethanol-induced place preference in mice with ethanol physical dependence.
Topics: Acamprosate; Administration, Inhalation; Alcohol Deterrents; Alcoholism; Animals; Conditioning, Psyc | 2013 |
Acamprosate produces its anti-relapse effects via calcium.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Calcium; Disease Models, Animal; Dose-Response | 2014 |
[Acamprosate has not proved to be efficient in the treatment of alcoholism in primary care medicine].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Primary Health Care; Taurine; Treatment Failure | 2013 |
Acamprosate: an alcoholism treatment that may not be what we thought.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Calcium; Humans; Male; Taurine | 2014 |
Effect of taurine in chronic alcoholic patients.
Topics: Aged; Alanine Transaminase; Alcohol Dehydrogenase; Alcoholism; Aldehyde Dehydrogenase; Antioxidants; | 2014 |
[Pharmacological profiles and clinical roles of acamprosate (Regtect(®) tablets 333 mg) for the maintenance of abstinence in alcohol-dependent patients].
Topics: Acamprosate; Alcoholism; Animals; Clinical Trials as Topic; Feeding Behavior; Humans; Tablets; Tauri | 2014 |
[Drug therapy supports reduction of alcohol consumption].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Taurine | 2014 |
Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Female; Gen | 2014 |
Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Bipolar Disorder; Female; Huma | 2014 |
Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Dehydroepiandrosterone; Dose-Response Relationsh | 2015 |
Acamprosate, alcoholism, and abstinence.
Topics: Alcoholism; Ethanol; Female; Humans; Male; Substance Withdrawal Syndrome; Taurine | 2015 |
[Acamprosate and naltrexone: similar efficacy for relapse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Recurrence; T | 2014 |
Effects of acamprosate on attentional set-shifting and cellular function in the prefrontal cortex of chronic alcohol-exposed mice.
Topics: Acamprosate; Action Potentials; Alcohol Drinking; Alcoholism; Animals; Attention; Ethanol; Membrane | 2015 |
Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics; Alcoholism; Baclofen; Carcinoma, Hepatocellular; Drug C | 2016 |
Factors Affecting Ethanol-Induced Conditioned Place Preference and Locomotor Sensitization in Mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Association Learning; Condit | 2015 |
Oral and long-acting injectable naltrexone: removal of boxed warning for hepatotoxicity.
Topics: Alcoholism; Ethanol; Female; Humans; Male; Substance Withdrawal Syndrome; Taurine | 2015 |
Does Acamprosate Really Produce its Anti-Relapse Effects via Calcium? No Support from the PREDICT Study in Human Alcoholics.
Topics: Alcohol Deterrents; Alcoholism; Animals; Calcium; Humans; Male; Taurine | 2016 |
Reply to: Does acamprosate really produce its anti-relapse effects via calcium? No support from the PREDICT study in human alcoholics.
Topics: Alcohol Deterrents; Alcoholism; Animals; Calcium; Humans; Male; Taurine | 2016 |
Association between a brief alcohol craving measure and drinking in the following week.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; | 2016 |
National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Drug Administration Schedule; Female; | 2016 |
Pharmacotherapy for Adults with Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; T | 2016 |
Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Glutamic Acid; Gyrus Cinguli; Humans; Ma | 2016 |
Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Topics: Acamprosate; Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined M | 2017 |
Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Australia; | 2017 |
[Pharmacotherapy of alcohol dependence].
Topics: Acamprosate; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Ambulatory Care; Anticonvu | 2008 |
Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Darkness; Disease Models, An | 2008 |
Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy, Combi | 2008 |
Successful acamprosate treatment of alcohol dependence in schizophrenia.
Topics: Acamprosate; Aged; Alcohol Deterrents; Alcoholism; Comorbidity; Female; Humans; Schizophrenia; Tauri | 2008 |
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Delayed-Action Preparations; Disulfiram; | 2009 |
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Body Weight; Conditioning, O | 2009 |
The effects of taurine, hypotaurine, and taurine homologs on erythrocyte morphology, membrane fluidity and cytoskeletal spectrin alterations due to diabetes, alcoholism and diabetes-alcoholism in the rat.
Topics: Alcoholism; Animals; Cytoskeleton; Diabetes Mellitus, Experimental; Erythrocytes; Male; Membrane Flu | 2009 |
Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Humans; Naltrexone; Narcotic Antag | 2009 |
Treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Anta | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism | 2009 |
Brain injury and recovery following binge ethanol: evidence from in vivo magnetic resonance spectroscopy.
Topics: Alcoholism; Analysis of Variance; Animals; Aspartic Acid; Body Weight; Brain Injuries; Brain Mapping | 2010 |
The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Diffusion of Innovation; Foll | 2010 |
Pharmacotherapies for alcoholism: the old and the new.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Dis | 2010 |
Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benef | 2010 |
Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
Topics: Acamprosate; Administration, Oral; Adult; Age Factors; Alcohol Deterrents; Alcoholism; Ambulatory Ca | 2010 |
Chronic alcohol exposure increases circulating bioactive oxidized phospholipids.
Topics: Administration, Oral; Alcoholism; Animals; Diet; Ethanol; Fatty Liver; Feeding Behavior; Humans; Liv | 2010 |
Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Alcohols; Atrial Natriuretic Factor; Female; GAT | 2011 |
Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Dru | 2010 |
Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Corpus Striatum; Disease Mod | 2010 |
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltr | 2010 |
Gambling on acamprosate: a case report.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Second-Generation; Comorbidity; | 2010 |
[Cochrane review about the effect of acamprosate].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Evidence-Based Medicine; Humans; Taurine; Treatment Out | 2010 |
Comparison of healthcare utilization among patients treated with alcoholism medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Female; Health | 2010 |
Effectiveness of acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Secondary Prevention; Taurine; Treatment Outcom | 2011 |
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Chi-Square Distribution; Databases, Factual; Dis | 2011 |
Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Topics: Acamprosate; Alcoholism; Alleles; Disulfiram; Genetic Markers; Humans; Naltrexone; Narcotic Antagoni | 2012 |
Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.).
Topics: Alcohol Drinking; Alcoholism; Behavior, Addictive; Bipolar Disorder; Depression; Female; Humans; Mal | 2012 |
Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Disulfiram; | 2013 |
Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Cognitive Behavioral Therapy; C | 2002 |
The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction.
Topics: Acamprosate; Adult; Alcoholism; Analysis of Variance; Chi-Square Distribution; Europe; Female; Forec | 2002 |
[Deficits in preventing recurrence in alcoholic patients. Withdrawal--and immediately back to the bottle].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Co | 2003 |
Physicians' opinions about medications to treat alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Clinical Competence; Disu | 2003 |
Acamprosate does not induce a conditioned place preference and reveals no state-dependent effects in this paradigm.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Conditioning, Classical; Male; Movement; Rats; | 2003 |
[Preventing recurrence after alcohol withdrawal treatment with drugs. Reducing the drive to drink].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Ther | 2003 |
A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disruptive, Impulse Control, and Conduct Disorde | 2003 |
New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Humans; Naltrexone; Taurine; Treatmen | 2003 |
THE URINARY EXCRETION OF FREE TAURINE IN ACUTE AND CHRONIC DISEASE, FOLLOWING SURGICAL TRAUMA, AND IN PATIENTS WITH ACUTE ALCOHOLISM.
Topics: Adrenal Cortex Hormones; Alcoholism; Biliary Tract; Biomedical Research; Cholecystitis; Cholelithias | 1964 |
[Psychosocial treatment plus drug prophylaxis. Fewer recurrences after alcohol withdrawal].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Randomized | 2003 |
Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, | 2004 |
Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support.
Topics: Acamprosate; Adult; Alcoholism; Analysis of Variance; Confidence Intervals; Female; Humans; Linear M | 2004 |
Does acamprosate improve reduction of drinking as well as aiding abstinence?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Humans; Sec | 2003 |
Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomography.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Carbon Radioisotopes; Humans; Isotope L | 2004 |
The mosaic of addiction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, | 2004 |
[Acamprosate--new preclinical research aspects].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Drug Evaluation, Preclinical; Ethanol; | 2003 |
Effect of neramexane on ethanol dependence and reinforcement.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Central Nervous System Depre | 2004 |
Acamprosate campral for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Diarrhea; Disulfiram; Drug Therapy, Combination; Humans | 2005 |
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Amino Acid Transport System X-AG; Ani | 2005 |
[The pharmacologic treatment of the alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; T | 2004 |
New drug released for alcohol dependency.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Taurine | 2005 |
Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; bet | 2005 |
A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naltrex | 2005 |
The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.
Topics: Acamprosate; Acute Disease; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Caudate Nucle | 2005 |
Production of reactive oxygen species following acute ethanol or acetaldehyde and its reduction by acamprosate in chronically alcoholized rats.
Topics: Acamprosate; Acetaldehyde; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Ethanol; | 2005 |
Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.
Topics: Academies and Institutes; Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cooperative Behavior | 2005 |
Drug treatment for alcoholism today.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Na | 2005 |
Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Mo | 2005 |
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Drug Monitoring; Drug-Related | 2005 |
N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice.
Topics: Acamprosate; Alcoholism; Animals; Brain; Cyclopentanes; Dizocilpine Maleate; Dose-Response Relations | 2006 |
New alcohol abuse drugs emerging. Anti-craving meds are finally here to treat alcohol dependence, recognized as a disease of the brain.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 2005 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Femal | 2006 |
The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Attitude to Health; Disulfiram; Humans; Male; Na | 2006 |
Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Appetitive Behavior; Dose-Re | 2006 |
Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; beta-Endorphin; Bioma | 2006 |
[Maintaining abstinence after alcohol detoxification].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ambulatory Care; Behavior Therapy; Cl | 2006 |
Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Humans; Inject | 2006 |
Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Drug Therapy, Combination; Fem | 2006 |
Is acamprosate use in alcohol dependence treatment reflected in improved subjective health status outcomes beyond cognitive behavioural therapy alone?.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality | 2006 |
[Drugs against alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Drug Evaluation; Humans; Naltrexone; Narcot | 2006 |
Acamprosate and primitive reflexes.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain Stem; Humans; Male; Middle Aged; Reflex; Taurine | 2007 |
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Dose- | 2007 |
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; | 2008 |
The effect of acamprosate on alcohol and food craving in patients with alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Body Mass Index; Cognitive Behavioral Therapy; C | 2008 |
New therapies for alcohol dependence open options for office-based treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family Practice; Fructose | 2007 |
Somatic configuration: a model for an integrated approach to the understanding of disease.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bayes Theorem; Cognitive Behavioral Therapy; Decision T | 2007 |
The application of machine learning techniques as an adjunct to clinical decision making in alcohol dependence treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Artificial Intelligence; Bayes Theorem; Cognitive Behav | 2007 |
Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; beta-Endorphin; Disease Mode | 2008 |
High temporal resolution of amino acid levels in rat nucleus accumbens during operant ethanol self-administration: involvement of elevated glycine in anticipation.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Amino Acids; Animals; Central Nervous System | 2008 |
From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Naltrexone; | 2008 |
Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Behavi | 2008 |
Effect of ethanol on taurine concentration in the brain.
Topics: Alcoholism; Animals; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Ethanol; Humans; Male; Rats; Sl | 1980 |
Interactions between ethanol and agents that act on the NMDA-type glutamate receptor.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Drug Interactions; Ethanol; Excitatory | 1996 |
International update: new findings on promising medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity | 1996 |
Alternatives to naltrexone in animal models.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Drug Evaluation, Precl | 1996 |
Acute and chronic alcohol injections increase taurine in the nucleus accumbens.
Topics: Alcoholism; Animals; Ethanol; Extracellular Space; gamma-Aminobutyric Acid; Glutamic Acid; Injection | 1994 |
[Pharmacotherapy of alcoholism].
Topics: Acamprosate; Alcoholism; Female; Humans; Male; Substance-Related Disorders; Taurine | 1996 |
Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relations | 1997 |
New drug treatments for alcohol problems: a critical appraisal.
Topics: Acamprosate; Alcoholism; Anti-Anxiety Agents; Buspirone; Dopamine Antagonists; Humans; Naltrexone; N | 1997 |
Treating alcohol dependence. Acamprostate is another drug to help maintain abstinence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Taurine | 1997 |
Effects of muscimol or homotaurine on sleep-wake states in alcohol-dependent rats during withdrawal.
Topics: Alcoholic Intoxication; Alcoholism; Animals; Behavior, Animal; Body Weight; Central Nervous System D | 1998 |
Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cerebral Cortex; Culture Techniques; Dizocilpi | 1998 |
Teaching the brain to take drugs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Addictive; Brain; Cocaine; Cocaine-R | 1998 |
Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats.
Topics: Acamprosate; Alanine; Alcohol Deterrents; Alcoholism; Animals; Arginine; Aspartic Acid; Chromatograp | 1998 |
[Medical treatment of alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; T | 1998 |
Taurine: protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Adenosine Triphosphate; Alcoholism; Anima | 1998 |
New treatments for alcohol dependency better than old.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Taurine | 1999 |
The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cost-Benefit Analysis; Economics, Pharmaceutical; Germa | 1998 |
Prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family; Humans; Naltrexon | 1999 |
Medical allies against alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 1999 |
[Glutamate receptor agonists and alcohol dependence. Preclinical findings].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Chronic Disease; Disease Models, Animal; Human | 1999 |
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Dia | 1999 |
Taurine blocks the glutamate increase in the nucleus accumbens microdialysate of ethanol-dependent rats.
Topics: Alcoholism; Animals; Arginine; Central Nervous System Depressants; Ethanol; gamma-Aminobutyric Acid; | 2000 |
Acamprosate. Pharmacoeconomic implications of therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cost-Benefit Analysis; Costs and Cost Analysis; Humans; | 1999 |
Pharmacological validation of a new animal model of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Nalt | 2000 |
[Efficient prevention of relapse with acamprosate].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Recurrence; Taurine | 2000 |
An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Belgium; Combined Modality Therapy; Female; Foll | 2000 |
Can this pill stop you from hitting the bottle?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Humans; Motivation; Naltrexone; Narcotic An | 2001 |
Combined behavioral and pharmacologic treatments of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Na | 2001 |
Does the alcoholic's remedy come in a pill?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Excitatory Amino Acid Antagonists; Female; | 2001 |
Addiction medicine for the primary care physician.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; | 2001 |
Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol.
Topics: Acamprosate; Adaptation, Physiological; Alcohol Deterrents; Alcoholism; Amygdala; Animals; Behavior, | 2002 |
Investigation of the therapeutic efficacy of a taurine analogue during the initial stages of ethanol detoxification: preliminary studies in chronic alcohol abusers.
Topics: Acamprosate; Alcoholism; Amino Acids; Chlordiazepoxide; Chronic Disease; Ethanol; GABA Modulators; G | 2000 |
Drug treatments for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Substance Withdrawal Sy | 2002 |
Central nervous system mechanisms in alcohol relapse.
Topics: Acamprosate; Alcoholism; Animals; Behavior; Central Nervous System; Corticotropin-Releasing Hormone; | 2002 |
Potential neuroprotective effects of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Humans; Neuroprotective Agents; Substan | 2002 |
Effects of taurine on alcohol withdrawal.
Topics: Alcoholism; Chronic Disease; Ethanol; Humans; Substance Withdrawal Syndrome; Taurine | 1977 |
Acamprosate as cause of erythema multiforme contested.
Topics: Acamprosate; Alcoholism; Erythema Multiforme; Female; Herpes Genitalis; Humans; Liver Cirrhosis; Tau | 1992 |
Effects of alcohol dependence on shock-induced fighting: action of muscimol and homotaurine.
Topics: Aggression; Alcoholism; Animals; Body Weight; Electroshock; Ethanol; gamma-Aminobutyric Acid; Male; | 1992 |
Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats.
Topics: Acamprosate; Alcoholism; Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Ethanol; ga | 1992 |
Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour.
Topics: Acamprosate; Administration, Inhalation; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Anima | 1991 |
Acamprosate, citalopram, and alcoholism.
Topics: Acamprosate; Alcoholism; Citalopram; Clinical Trials as Topic; gamma-Glutamyltransferase; Humans; Ta | 1991 |
Acamprosate, citalopram, and alcoholism.
Topics: Acamprosate; Alcoholism; Citalopram; Humans; Patient Dropouts; Taurine | 1991 |
Similar antagonistic effects of Ca N-acetylhomotaurinate on depression of motor activity and lethality induced by acetaldehyde or ethanol.
Topics: Acamprosate; Acetaldehyde; Alcoholism; Amino Acids, Sulfur; Animals; Cations; Ethanol; Male; Mice; M | 1988 |
Sulfur amino acid metabolism in chronic relapsing pancreatitis.
Topics: Adult; Aged; Alcoholism; Amino Acids, Sulfur; Cholecystectomy; Chronic Disease; Cystathionine; Cyste | 1986 |
Effects of long term alcohol ingestion on glutathione metabolising enzymes and taurine contents in the myocardium of rats.
Topics: Alcoholism; Animals; Glutathione; Male; Myocardium; Organ Size; Rats; Taurine; Time Factors | 1986 |
Lowering of liver acetaldehyde but not ethanol concentrations by pretreatment with taurine in ethanol-loaded rats.
Topics: Acetaldehyde; Alcoholism; Aldehyde Dehydrogenase; Animals; Enzyme Activation; Ethanol; Liver; Male; | 1985 |